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1. Introduction 
This report describes and summarises results 
from the twenty-third proficiency test trial 
conducted by the National Food Institute (DTU 
Food) as the EU Reference Laboratory for 
Antimicrobial Resistance (EURL-AR). This 
proficiency test focuses on antimicrobial 
susceptibility testing (AST) of Salmonella and 
Campylobacter and is the eleventh External 
Quality Assurance System (EQAS) conducted 
for these microorganisms (the first was EQAS 
2006). In addition, the proficiency test includes 
categorisation of the relevant Salmonella strains 
as presumptive AmpC-, ESBL-, or 
carbapenemase producing organisms, and 
identification of the Campylobacter species as 
either C. jejuni or C. coli. 
In addition, for the ninth time, an optional 
element was included, consisting of genotypic 
characterization of antimicrobial resistance 
genes by PCR and/or sequencing. This optional 
component included characterization of genes 
encoding AmpC, ESBL-, or carbapenemases in 
the Salmonella test strains. 
This EQAS aims to: i) monitor the quality of AST 
results produced by National Reference 
Laboratories (NRL-AR), ii) identify laboratories 
which may need assistance to improve their 
performance in AST, and iii) determine possible 
topics for further research or collaboration. 
In reading this report, the following important 
considerations should be taken into account: 
1) Expected results were generated by 
performing Minimum Inhibitory Concentration 
(MIC) determinations for all test strains in two 
different occasions at the Technical University of 
Denmark, National Food Institute (DTU Food). 
These results were then verified by the Centers 
for Disease Control and Prevention, Georgia, US 
(Salmonella) and the United States Food and 
Drug Administration (FDA), Centre for Veterinary 
Medicine, Maryland, US (Campylobacter). 
Finally, a fourth MIC determination was 
performed at DTU Food after preparation of the 
agar stab culture/charcoal swab for shipment to 
participants to confirm that the vials contained 
the correct strains with the expected MIC values. 
2) Evaluation is based on interpretations of AST 
values determined by the participants. This is in 
agreement with the method used by Member 
States (MS) to report AST data to the European 
Food Safety Authority (EFSA), and complies with 
the main objective of this EQAS, i.e. to evaluate 
and improve the comparability of surveillance 
data on antimicrobial susceptibility of Salmonella 
and Campylobacter reported to EFSA by 
different laboratories, as stated in the protocol. 
3) The EURL-AR network agreed on setting the 
accepted deviation level for laboratory 
performance on AST to 5%. For the optional 
genotypic characterisation, no specific 
acceptance level has been set. 
Evaluation of a result as “deviating from the 
expected interpretation” should be carefully 
analyzed in a self-evaluation procedure 
performed by the participant including also 
considerations related to any corrective actions 
introduced in the laboratory. Note, that since 
methods used for MIC determination have 
limitations, it is not considered a mistake to 
obtain a one-fold dilution difference in the MIC of 
a specific antimicrobial when testing the same 
strains. If, however, the expected MIC is close to 
the breakpoint value for categorising the strain 
as susceptible or resistant, a one-fold dilution 
difference - which is acceptable - may result in 
two different interpretations, i.e. the same strain 
can be categorised as susceptible or resistant. 
This result may be evaluated as correct based 
on the MIC-value produced but incorrect when 
the evaluation is based on the interpretation of 
the MIC value. This report is based on evaluation 
of AST interpretations, therefore some 
participants may find their results classified as 
incorrect even though the actual MIC they 
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reported is only a one-fold dilution away from the 
expected MIC. In these cases, the participants 
should be confident about the good quality of 
their performance of AST by MIC. In the 
organization of the EQAS, we try to avoid these 
situations by choosing test strains with MIC 
values distant from the cut offs for resistance, 
which is not always feasible for all strains and all 
antimicrobials. Therefore, the EURL-AR network 
unanimously established in 2008 that if there are 
less than 75% correct results for a specific 
strain/antimicrobial combination, the reasons for 
this situation must be further examined and, on 
selected occasions explained in details case by 
case, these results may subsequently be omitted 
from the evaluation report.  
This report is approved in its final version by a 
technical advisory group composed by 
competent representatives from all NRL-ARs. 
This group meets annually at the EURL-AR 
workshop. 
All conclusions presented in this report are 
publically available. Participating laboratories 
are identified by codes and each code is known 
only by the corresponding laboratory. The full list 
of laboratory codes is confidential and known 
only by relevant representatives of the EURL-AR 
and the EU Commission.  
The EURL-AR is accredited by DANAK as 
provider of proficiency testing (accreditation no. 
516); working with zoonotic pathogens and 
indicator organisms as bacterial isolates 
(identification, serotyping and antimicrobial 
susceptibility testing). 
2. Materials and Methods  
2.1 Participants in EQAS 2017 
A pre-notification (App. 1) to announce the 
EURL-AR EQAS on AST of Salmonella and 
Campylobacter was distributed on the 25th  
August 2017 by e-mail to the 44 laboratories in 
the EURL-AR-network including all EU countries 
and Iceland, the former Yugolsav Republic of 
Macedonia (FYROM), Norway, Serbia, 
Switzerland and Turkey. All EU MS as well as 
Iceland, Norway, and Switzerland were 
represented as participants for both Salmonella 
and Campylobacter. In addition to the AST of 
Salmonella and Campylobacter, an optional 
genotypic characterization by PCR/sequencing 
of antimicrobial resistance genes of the AmpC-, 
ESBL- and carbapenemase-producing 
Salmonella test strains was offered.  
Appendix 2 shows that 29 of the 32 participating 
NRLs were appointed by the individual Member 
States’ Competent Authority. Five additional 
laboratories were included; one from each of the 
following countries: Iceland, the Netherlands, 
Norway, Spain, and Switzerland. These were 
invited to take part in the EQAS 2017 on the 
basis of their participation in previous EQAS 
iterations and/or affiliation to the EU network. 
These laboratories were charged a fee for their 
participation in the EQAS, whereas the NRLs 
from EU Member States participated free of 
charge. 
Figure 1 illustrates that of the 31 participating 
countries, all tested both Salmonella and 
Campylobacter. Thirteen laboratories 
participated in the optional genotypic 
characterisation of the ESC-resistant (Extended 
Spectrum Cephalosporin-resistant) Salmonella 
test strains (not illustrated in Figure 1; see 
Appendix 2). 
The results from the NRLs designated by the MS 
are presented and evaluated in this report in 
addition to national reference laboratories in 
affiliated non-MS. In total, results from 31 
countries consisting of 31 laboratories 
submitting Salmonella results and 30 
laboratories submitting Campylobacter results. 
Twelve sets of results in relation to the optional 
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Figure 1: Participating countries that performed antimicrobial susceptibility testing of Salmonella 
and Campylobacter in 2017. 
genotypic characterization is evaluated. Results 
from the two laboratories not designated by the 
MS but enrolled in the EQAS are not further 
presented or evaluated in this report. 
2.2 Strains 
Eight Salmonella strains and eight 
Campylobacter strains were selected for this trial 
among isolates from the strain collection at DTU 
Food on the basis of antimicrobial resistance 
profiles and MIC values. For quality assurance 
purposes, one strain per bacterial species has 
been included in all EQAS iterations performed 
to date, representing an internal control. 
Prior to distribution of the strains, AST was 
performed on the Salmonella and 
Campylobacter strains at DTU Food and verified 
by the Centers for Disease Control and 
Prevention (CDC), Georgia, US (Salmonella) 
and the United States Food and Drug 
Administration (FDA), Centre for Veterinary 
Medicine, Maryland, US (Campylobacter). When 
MIC-values were not in agreement but varied +/- 
one dilution-step, the value obtained by DTU 
Food was selected as the reference value. The 
obtained MIC values served as reference for the 
test strains (App. 3a and 3b). Results from the 
following antimicrobials were not verified by CDC 
for Salmonella: cefepime, cefotaxime, 
cefotaxime/clavulanic acid, ceftazidime, 
ceftazidime/clavulanic acid, colistin, ertapenem, 
imipenem, temocillin, tigecycline and 
trimethoprim, and results from the following 
antimicrobials were not verified by FDA  for 
Campylobacter: streptomycin. 
Reference strains Escherichia coli CCM 3954 
(ATCC 25922) and Campylobacter jejuni CCM 
6214 (ATCC 33560) were provided to new 
participating laboratories with instructions to 
store and maintain them for quality assurance 
purposes and future EQAS trials. 
2.3 Antimicrobials 
The antimicrobials tested in this EQAS are listed 
in the protocol (App. 4b).  
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The antimicrobials tested correspond to the 
panel of antimicrobials listed in Decision 
2013/652/EU.  
The method applied for the AST was the ISO 
standard, ISO 20776-1 “Clinical laboratory 
testing and in vitro diagnostic test system – 
Susceptibility testing of infectious agents and 
evaluation of performance of antimicrobial 
susceptibility test devices”, and, in addition, the 
following guidelines/standards from the Clinical 
and Laboratory Standards Institute (CLSI) were 
applied: Document M7-A10 (2015) “Methods for 
Dilution Antimicrobial Susceptibility Tests for 
Bacteria That Grow Aerobically; Approved 
Standard - Tenth Edition”; document M100S, 
27th ed. (2017) “Performance Standards for 
Antimicrobial Susceptibility Testing” (CLSI 
Supplement M100S) and document VET01-A4 
(2013) “Performance Standards for Antimicrobial 
Disk and Dilution Susceptibility Tests for 
Bacterial Isolated From Animals” (Approved 
Standard – Fourth Edition). 
MIC results were interpreted by using the 
interpretative criteria listed in Decision 
2013/652/EU. Where values were not available, 
the list of interpretative criteria was 
supplemented with CLSI-interpretative criteria 
as or tentative values as described and indicated 
in the protocol (App. 4). No interpretative criteria 
were available to determine the interpretation of 
MIC-values for cefepime. Results of ESC-
resistance detection tests were interpreted 
according to the most recent EFSA 
recommendations also included as an appendix 
in the EQAS protocol (Appendix 4).  
The selection of antimicrobials used in the trial 
for Salmonella were: ampicillin (AMP), 
azithromycin (AZI), cefepime (FEP), cefotaxime 
(FOT), cefotaxime/clavulanic acid (FOT/Cl), 
cefoxitin (FOX), ceftazidime (TAZ), 
ceftazidime/clavulanic acid (TAZ/Cl), 
chloramphenicol (CHL), ciprofloxacin (CIP), 
colistin (COL), ertapenem (ERT), gentamicin 
(GEN), imipenem (IMI), meropenem (MER), 
nalidixic acid (NAL), sulfonamides 
(sulfamethoxazole) (SMX), tetracycline (TET), 
tigecycline (TGC), temocillin (TRM) and 
trimethoprim (TMP). 
Minimum Inhibitory Concentration (MIC) 
determination of the Salmonella test strains was 
performed using the Sensititre system (EUVSEC 
and EUVSEC2) from Trek Diagnostic Systems 
Ltd, UK. The confirmatory tests for ESC-
resistance included MIC determination by 
microbroth dilution.  
For Campylobacter the following antimicrobials 
were included: ciprofloxacin (CIP), erythromycin 
(ERY), gentamicin (GEN), nalidixic acid (NAL), 
streptomycin (STR), and tetracycline (TET). MIC 
determination for the Campylobacter testing, 
was performed using the Sensititre systems 
(EUCAMP2) from Trek Diagnostic Systems Ltd, 
UK, according to guidelines from the CLSI 
document M45-A2 (2010) “Methods for 
Antimicrobial Dilution and Disk Susceptibility 
Testing of Infrequently Isolated or Fastidious 
Bacteria” (Approved Guideline – Second Edition) 
and VET01-S2 (2013) “Performance Standards 
for Antimicrobial Disk and Dilution Susceptibility 
Tests for Bacterial Isolated From Animals” 
(Second Informational Supplement). 
Participants of the Campylobacter EQAS were 
additionally requested to identify the species of 
the Campylobacter spp. as either C. jejuni or C. 
coli. 
2.4 Distribution 
On 30 October 2017, bacterial strains in agar 
stab cultures (Salmonella spp.) or charcoal 
swabs in transport media (Stuarts) 
(Campylobacter spp.) together with a welcome 
letter (App. 4a) were dispatched in double pack 
containers (class UN 6.2) to the participating 
laboratories. The shipment (UN3373, biological 
substances category B) was sent according to 
International Air Transport Association (IATA) 
regulations.  
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2.5 Procedure 
Protocols and all relevant information were 
uploaded on the EURL-AR website 
(http://www.eurl-ar.eu), thereby EQAS 
participants could access necessary information 
at any time.  
Participants were instructed to subculture 
charcoal swabs immediately, store the agar 
stabs at 4ºC (dark) and the freeze-dried strains 
cool and dark until performance of AST. 
Information related to the handling of the test 
strains and reference strains (App. 4b, c, d, e) 
was made available. Participants receiving an 
ATCC reference strain were requested to save 
and maintain this strain for future proficiency 
tests. 
The participants were instructed to apply the 
interpretative criteria listed in the protocol (App. 
4). Instructions for interpretation of AST results 
allowed for categorisation of results as resistant 
or susceptible. Categorisations as ‘intermediate’ 
were not accepted.  
The EURL-AR is aware that there are two 
different types of interpretative criteria of results, 
clinical breakpoints and epidemiological cut-off 
values. The terms ‘susceptible’, ‘intermediate’ 
and ‘resistant’ should be reserved for 
classifications made in relation to the therapeutic 
application of antimicrobial agents. When 
reporting data using epidemiological cut-off 
values, bacteria should be reported as ‘wild-type’ 
or ‘non-wild-type’ (Schwarz et al., 2010). Due to 
the different methods of AST used by the 
participants and also to simplify the interpretation 
of results, throughout this report, we will still 
maintain the terms susceptible and resistant, 
even in cases where we are referring to wild-type 
and non-wild-type strains. 
As regards the method for performing the 
antimicrobial susceptibility testing, the protocol 
referred to Decision 2013/652/EU and instructed 
participants to perform the international 
reference method for antimicrobial susceptibility 
testing. I.e. dilution methods performed 
according to the methods described by the 
European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) and the Clinical 
and Laboratory Standards Institute (CLSI), 
accepted as the international reference method 
(ISO standard 20776-1:2006).  
A mandatory part of the proficiency test was to 
detect ESC-resistant strains and interpret results 
according to the most recent EFSA 
recommendations as described in the protocol.  
Results from QC reference strains would consist 
of MIC values for the reference strains E. coli 
(ATCC 25922) and C. jejuni (ATCC 33560). The 
results were evaluated towards the quality 
control ranges according to the relevant 
guidelines; i.e. the CLSI documents VET01-S2 
(2013) or M100S, 27th ed. (2017) (App. 5). 
For the optional genotypic characterisation of the 
genes encoding for resistance to extended-
spectrum beta lactam antimicrobials in the 
Salmonella test strains, participating laboratories 
were requested to report the genes. The 
organizers, however, decided to include in the 
selection of isolates with none-ESC-resistant 
TEM-beta-lactamases encoded by blaTEM-1 as 
an expected gene. The genes listed in the table 
in the protocol (App. 4b) were included in the 
test. Identification of additional genes not listed 
in the protocol was not evaluated by the 
database. The results were evaluated based on 
the actual genes and variants identified. 
The participating laboratories were encouraged 
to use their own laboratory’s method(s) for the 
genotypic characterisation. The expected results 
for this component of the EQAS were obtained 
by whole-genome-sequencing and subsequent 
analysis using the ResFinder 3.0 platform 
available at 
http://cge.cbs.dtu.dk/services/ResFinder/. The 
positive identification of genes was not verified 
elsewhere. 
All participating laboratories were invited to enter 
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the obtained results into an electronic record 
sheet at the EURL-AR web-based database 
through a secured individual login and 
password. The record sheet contained space for 
reporting the results obtained for the QC 
reference strains.  
In addition, participants were encouraged to 
complete an evaluation form available at the 
EURL-AR database with the aim to improve 
future EQAS trials. 
The database was finally closed and evaluations 
were made available to participants on January 
3, 2018. After this date, the participants were 
invited to login to retrieve an individual, 
database-generated report which contained an 
evaluation of the submitted results including 
possible deviations from the expected 
interpretations. Deviations in the interpretation 
as resistant or susceptible were categorised as 
‘incorrect’, as were also deviations concerning 
confirmation of an isolate as extended spectrum 
beta-lactamase- (ESBL-), ampC- or 
carbapenemase-producer. 
3. Results
The participants were asked to report results, i.e. 
MIC values and the categorisation as resistant or 
susceptible. Only the categorisation was 
evaluated, whereas the MIC values were used 
as supplementary information. 
3.1 Data omitted from the report 
As mentioned in the introduction, the EURL-AR 
network established that data should be 
examined and possibly omitted from the general 
analysis if there are less than 75% correct results 
based on strain/antimicrobial combination (see 
Appendix 7a and 7b for an overview of 
correct/incorrect results). In the present EQAS 
this occurred in three cases which have been 
examined and consequently omitted from the 
analysis; 1) S-12.4/cefotaxime (expected 
interpretation was ‘resistant’, however, 42% (16 
laboratories) found the strain susceptible in 
either panel 1 or panel 2. All but two of the 
deviating interpretations were based on MIC 
values one step from the expected; 2) S-
12.5/colistin (expected interpretation was 
‘resistant’, however, 40% found the strain 
resistant to colistin. All but one of the deviating 
interpretations were based on MIC values one 
step from the expected; 3) S-12.7/ceftazidime 
(expected interpretation was ‘susceptible’), 
however, 26% (based on both panel 1 and panel 
2) found the strain resistant to ceftazidime. All of
the deviating interpretations were based on MIC
values within one step from the expected. 
For Campylobacter, it appeared that strain C-
12.1 caused problems for six laboratories as the 
strain was expected to be fully susceptible, 
however, the six laboratories in question 
reported resistance to ciprofloxacin, nalidixic 
acid and tetracycline based on high MIC-values 
not close to the breakpoint. It was therefore 
concluded that the culture had likely contained a 
mixed culture and it was decided to exclude the 
results of the six laboratories in question in 
relation to C-12.1. 
3.2 Methods 
Results obtained by broth microdilution were 
accepted and evaluated together as they are 
both quantitative methods giving results 
corresponding to the MIC of the bacterial strain 
tested.  
In the Salmonella as well as the Campylobacter 
trial, all 31 laboratories performed microbroth 
dilution. 
With the aim to conclude on the strains’ 
presumptive ESBL, AmpC or carbapenemase 
phenotype, two panels of antimicrobials were 
included in the testing of the Salmonella strains 
as also specified in the EU regulation 
2013/652/EU. The test strains found resistant to 
cefotaxime, ceftazidime or meropenem on the 
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Figure 2: A comparison between the EURL-AR EQAS’s since 2006, showing the total percentage of 
deviations for antimicrobial susceptibility testing performed by participating laboratories.  
first panel (see 2013/652/EU, Table 1) were 
additionally tested on the second panel (see 
2013/652/EU, Table 4) according to the protocol 
indications.  
3.3 Deviations, overall 
The list of deviations is presented in Appendix 8a 
and 8b. Figure 2 shows the total percentage of 
deviations from the expected results of AST 
performed by participating laboratories. The 
internal control strains mainly followed the trend 
in deviation level of the different EQAS trials 
(Figure 2), only, for 2017 the deviation level 
related to the Campylobacter internal control 
dropped to 0%. Overall, the deviation levels in 
2017 are acceptable for both the Salmonella and 
the Campylobacter trials.  
3.3.1 Salmonella trial 
For the Salmonella strains, 99.3% of the AST’s 
were interpreted correctly. The number of AST’s 
performed and the percentage of correct results 
for the individual strains in the EQAS, are listed 
in Table 1. Variations of obtained correct results 
ranged from 97.6-100% between the Salmonella 
strains. Table 2 illustrates the percentage of 
correct AST per antimicrobial by bacterial 
species. The level of correct AST was at 97.3% 
(ceftazidime) or above, for all the Salmonella test 
strains.  
ESC-resistant Salmonella test strains 
Confirmation of beta-lactamase production is a 
mandatory component of this EQAS.  
According to the protocol, which was based on 
the EFSA recommendations, the confirmatory 
test for ESC-resistant isolates requires use of 
both cefotaxime (FOT) and ceftazidime (TAZ) 
alone and in combination with a β-lactamase 
inhibitor. The MIC value for either antimicrobial 
agent (FOT or TAZ) tested in combination with 
clavulanic acid should be compared to the 
corresponding MIC when tested alone. Synergy 
is indicated for one or both cephalosporins if a 
three dilution steps difference is observed 
between the two MIC values (i.e. if the 
FOT:CTX/Cl or TAZ:TAZ/Cl ratio ≥8) (CLSI 
M100S Table 2A; Enterobacteriaceae). 
Participants were instructed to test strains 
presenting resistance to cefotaxime (FOT), 
ceftazidime (TAZ or meropenem (MERO) on the 
second panel of antimicrobials. 
The classification of the phenotypic results was 
based on the most recent EFSA 
recommendations indicating as indicated in the 
protocol (Appendix 4). 
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Table 1. The number of AST performed and the percentage of correct results for each strain of Salmonella (panel 1 
and panel 2) and Campylobacter. 
EQAS 2017 – Salmonella EQAS 2017 – Campylobacter 
Test strain AST in total % correct Test strain AST in total % correct 
S-12.1 635 99.2 C-12.1 (C. jejuni) 138 100.0 
S-12.2 635 99.2 C-12.2 (C. jejuni) 180 100.0 
S-12.3 634 99.8 C-12.3 (C. jejuni) 180 98.9 
S-12.4 540 97.6 C-12.4 (C. jejuni) 180 99.4 
S-12.5 395 100.0 C-12.5 (C. jejuni) 180 98.3 
S-12.6 426 100.0 C-12.6 (C. coli) 180 99.4 
S-12.7 574 99.7 C-12.7 (C. coli) 180 98.3 
S-12.8 635 98.9 C-12.8 (C. jejuni) 180 100.0 
Table 2: Percentage of correct antimicrobial 
susceptibility tests per antimicrobial by 
microorganism.  
Antimicrobial Salmonella Campylobacter 
Ampicillin 99.2 - 
Azithromycin 99.5 - 
Cefotaxime 100.0 - 
Cefoxitin 98.3 - 
Ceftazidime 97.3 - 
Chloramphenicol 99.6 - 
Ciprofloxacin 99.2 98.7 
Colistin 100.0 - 
Ertapenem 100.0 - 
Erythromycin 100.0 
Gentamicin 100.0 100.0 
Imipenem 97.8 - 
Meropenem 100.0 - 
Nalidixic acid 100.0 99.1 
Streptomycin 99.1 
Sulphonamides 97.6 - 
Temocillin 97.7 - 
Tetracycline 100.0 98.7 
Tigecycline 99.6 - 
Trimethoprim 100.0 - 
In this EQAS, all laboratories uploaded results 
for the strains exhibiting resistance to the 
cephalosporins tested. 
The strains S-12.1 and S-12.8 were 
carbapenemase producers, the strains S-12.2, 
S-12.3, and S-12.7 were ESBL-producers and
strain S-12.4 which fell into the category of 
AmpC-phenotype. For strain S-12.4, the
resistance mechanism is not known, and the 
phenotype is unusual (susceptibility to ampicillin) 
and therefore a categorisation as ‘unusual 
phenotype’ was also accepted.  
In total, the categorisation as ESBL-, AmpC- or 
carbapenemase-producer was correct in 241 out 
of 248 reported results. The results that were 
considered incorrect were all related to strain S-
12.4, as seven participants had indicated this 
strain as ‘no ESBL, AmpC- or carbapenemase’-
producer. 
3.3.2 Campylobacter trial 
For the Campylobacter strains, 99.3% of AST’s 
were correctly tested. Table 1 presents that the 
variation in the obtained correct results ranged 
from 98.3-100% and Table 2 illustrates that the 
percentage of correct AST per antimicrobial were 
all above 98.7%. 
The participants were requested to identify the 
Campylobacter species. All 30 laboratories 
delivered in total 233 results of which all were in 
accordance with the expected. 
3.4 Deviations by laboratory 
Figure 3 and 4 illustrate the percentage of 
deviations for each participating laboratory. The 
laboratories are ranked according to their 
performance determined by the percentage of 
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Table 3: Overview of ESBL-, AmpC- and carbapenemase-producing Salmonella test strains and proportion of 
laboratories that obtained the expected result; number and percentages of laboratories which correctly detected and 
confirmed the ESBL-, AmpC- and carbapenemase-producing Salmonella strains.  
Fields shaded in grey with numbers in italics indicate an unexpected result. 
Strain code S-12.1 S-12.2 S-12.3 S-12.4 S-12.7 S-12.8
ESC-resistance genes 
harboured in the test strain 
blaNDM-1 
blaCMY-16 
blaCTX-M-9 
blaTEM-1B 
blaCTX-M-14b 
Unknown 
resistance 
mechanism 
blaCTX-M-14 
blaNDM-1 
blaCTX-M-15 
blaDHA-1
blaOXA-1
blaOXA-9
blaOXA-10
blaTEM-1B 
ESBL-, AmpC- and carbapenemase-
producing strain – expected results carbapenemase ESBL ESBL 
AmpC 
Unusual phenotype ESBL carbapenemase 
O
bt
ai
ne
d 
re
su
lts
 
Confirmed ESBL-producer - 31/31 (100%) 31/31 (100%) - 31/31 (100%) - 
Confirmed ESBL + AmpC-
producer - - - - - - 
Confirmed AmpC-producer - - - 22/31 (71%) - - 
Confirmed carbapenemase-
producer 31/31 (100%) - - - - 31/31 (100%) 
Confirmed unusual 
phenotype - - - 2/31 (6%) - - 
Not ESBL-, AmpC-  
or carbapenemase-producing - - - 7/31 (23%) - - 
Figure 3: Individual participants’ deviations in percent of their total number of Salmonella AST’s. 
Figure 4: Individual participants’ deviations in percent of their total number of Campylobacter AST’s. 
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Table 4 Obtained values for AST of E. coli ATCC 25922. 
AMP; ampicillin, FEP; cefepime FOT; cefotaxime, FOX; 
cefoxitin, TAZ; ceftazidime, CHL; chloramphenicol, CIP; 
ciprofloxacin, COL; colistin, ERT: ertapenem, GEN; 
gentamicin, IMI; imipenem, MER; meropenem, NAL; 
nalidixic acid, SMX; sulphonamides, TET; tetracycline, TGC; 
tigecycline, TMP; trimethoprim. 
MIC determination E. coli ATCC 25922 
Antimicrobial 
Proportion 
outside QC 
range 
Obtained values in MIC 
steps (min/max) 
Below lower 
QC limit 
Above 
upper QC 
limit 
Panel 1, AMP 0/31 (0%) - - 
Panel 1, FOT 1/30 (3%) - 1 step
Panel 1, TAZ 0/31 (0%) - - 
Panel 1, CHL 0/31 (0%) - - 
Panel 1, CIP 0/31 (0%) - - 
Panel 1, COL 0/31 (0%) - - 
Panel 1, GEN 1/31 (3%) - 1 step
Panel 1, MER 0/31 (0%) - - 
Panel 1, NAL 0/31 (0%) - - 
Panel 1, SMX 1/30 (3%) - 1 step
Panel 1, TET 0/31 (0%) - - 
Panel 1, TGC 0/31 (0%) - - 
Panel 1, TMP 2/31 (6%) 1 step - 
Panel 2, FEP 0/27 (0%) - - 
Panel 2, FOT 0/26 (0%) - - 
Panel 2, FOX 0/27 (0%) - - 
Panel 2, TAZ 2/27 (7%) 1 step - 
Panel 2, ERT 0/27 (0%) - - 
Panel 2, IMI 2/27 (7%) 1 step - 
Panel 2, MER 0/27 (0%) - - 
Table 5 Obtained values for AST of C. jejuni ATCC 33560. 
CIP; ciprofloxacin, ERY; erythromycin, GEN; gentamicin, 
NAL; nalidixic acid, TET; tetracycline. 
MIC determination C. jejuni ATCC 33560 
Antimicrobial 
Proportion 
outside QC 
range 
Obtained values in MIC 
steps (min/max) 
Below lower 
QC limit 
Above upper 
QC limit 
CIP 1/28 (4%) - 1 step
ERY 0/28 (0%) - - 
GEN 1/26 (4%) 1 step - 
NAL 2/27 (7%) 1 step - 
TET 1/27 (4%) - 1 step
deviating results in the antimicrobial 
susceptibility tests. 
3.4.1 Salmonella trial 
All 31 participating laboratories obtained a result 
below the acceptance limit at 5% deviations for 
the Salmonella strains. The maximum 
percentage of deviations was at 4.0%, 
presenting a very good result across the EURL-
AR network. 
3.4.2 Campylobacter trial 
In the Campylobacter trial, most laboratories 
performed very well. Applying the 5% 
acceptance threshold, 29 of 30 participating 
laboratories performed acceptably, with 25 
laboratories having no deviations (Figure 4). 
One laboratory presented a deviation level 
above the 5% acceptance level (#40). This 
laboratory was regarded as an outlier. 
3.5 Deviations by reference strains 
In the following section, deviations are defined 
as results of antimicrobial susceptibility tests on 
the reference strain that are outside the quality 
control (QC) acceptance intervals (App. 5).  
Obtained values from the participants’ testing of 
the QC strains are listed in Appendix 6a and 6b, 
and in Table 4 and 5. For the Salmonella and 
Campylobacter trial, 31 and 28 laboratories, 
respectively, uploaded data from QC-testing on 
the relevant reference strain. 
Appendix 6a presents the results for the 
reference strain E. coli ATCC 25922. Nine 
laboratories each produced one value outside 
the QC-limit. Table 4 illustrates the obtained 
results which are fully presented in Appendix 6a. 
Table 5 presents the proportion of the 
laboratories submitting AST-results for the C. 
jejuni reference strain ATCC 33560 with results 
below or above the QC interval. Five deviations 
were seen from four different laboratories. 
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3.6 Genotypic characterisation 
For the optional genotypic characterisation of the 
ESC-resistant Salmonella test strains, 12 
laboratories participated. In Appendix 9, 
information is presented on detected genes, 
primers used, and references for the method 
used. Three laboratories performed whole 
genome sequencing of the ESC-resistant 
Salmonella whereas the remaining eight 
laboratories indicated the use of various types of 
conventional PCR to identify the relevant genes. 
Table 6 indicate the obtained results, both on 
gene and variant level. Moreover, Figure 5 
indicates that six discordant results related to the 
genes and variant submitted by two different 
laboratories. These were related to the blaCMY-
gene and variants of the blaOXA and blaCTX-M-
genes. 
Figure 5: Individual participants’ deviations in percent of 
their total number of results from the detected genes.  
Table 6: Results from the participation of twelve laboratories in the optional genotypic characterisation component of the 
EQAS 
Strain code Expected gene Proportion of correct results (gene level) 
Proportion of correct 
results (variant level) 
Unexpected 
genes/variants identified 
S-12.1
blaNDM-1 12/12 (100%) 7/7 (100%) 
blaCMY-16 12/12 (100%) 6/6 (100%) 
S-12.2
blaCTX-M-9 12/12 (100%) 8/8 (100%) 
blaTEM-1/1B 12/12 (100%) 6/6 (100%) 
S-12.3 blaCTX-M-14b 12/12 (100%) 7/8 (88%) 
blaCMY-16 (gene and variant: n=1)
blaCTX-M-9 (variant: n=1) 
S-12.4 Unknown resistance mechanism - - 
S-12.7 blaCTX-M-14 12/12 (100%) 7/8 (88%) blaCTX-M-9 (variant: n=1) 
S-12.8
blaNDM-1 12/12 (100%) 7/7 (100%) 
blaCTX-M-1 (variant: n=1) 
blaOXA-17 (variant: n=1) 
blaCTX-M-15 10/10 (100%) 6/7 (86%) 
blaDHA-1 5/5 (100%) 2/2 (100%) 
blaOXA-1 6/6 (100%) 5/5 (100%) 
blaOXA-9 3/3 (100%) 3/3 (100%) 
blaOXA-10 5/5 (100%) 4/5 (80%) 
blaTEM-1/1B 8/8 (100%) 4/4 (100%) 
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4. Discussion
In both 2016 and 2017, 31 laboratories 
participated in the Salmonella EQAS, whereas 
for the Campylobacter EQAS, 31 participated in 
2016 and 30 in 2017. This allows for a fair 
comparison between the two EQAS periods.  
As also specified in the EU regulation 
2013/652/EU, all participants in the present 
EQAS performed AST by dilution methods, 
primarily as microbroth determination.  
This 2017 proficiency test is the fourth possibility 
of testing Salmonella and Campylobacter strains 
with the panels designed to follow the 
requirements of Decision 2013/652/EU.  
4.1 Salmonella trial 
Overall, the percentage of correct antimicrobial 
susceptibility test results of Salmonella was 
99.3%. All (n=31) participants obtained 
satisfactory results according to the level of 
acceptance (<5% deviation). When comparing 
between the antimicrobials, the testing of 
ceftazidime appeared to cause most problems 
(97.3% correct results).  
As indicated in Figure 2, the overall quality of the 
results in the 2017-EQAS would appear to be at 
the same high level as in 2015, also, the 
measure when comparing results obtained from 
testing the internal control strain indicates a 
steady and very good quality of Salmonella AST 
results.  
As indicated by Figure 3, all laboratories 
exhibited very good results with deviation levels 
below 5%. Follow-up has therefore not been 
necessary based on these results, and none of 
the laboratories were defined as outliers. 
For the E. coli reference strain, the obtained 
results were in general in agreement with the 
CLSI recommendations.  
Follow up on previous EQAS results is not 
relevant as no laboratories had deviation levels 
for the AST results above the acceptance limit in 
EQAS 2016.  
ESC-resistant Salmonella test strains 
The detection of ESC-resistant microorganisms 
remains to be important and is a mandatory part 
of this EQAS.  
Of the six Salmonella test strains relevant for this 
component of the EQAS (S-12.1, S-12.2, S-12.3, 
S-12.4, S-12.7, and S-12.8), two were
carbapenemase phenotypes and three were
ESBL-phenotypes. In addition, one (S-12.4) was
an AmpC-phenotype based on the criteria for
interpretation of the ESBL-, AmpC- and
carbapenemase indicated in the protocol. Only,
this particular strain presented an unusual
phenotype for an AmpC-producer, as it exhibited
no resistance to ampicillin, which many
participants noted as a comment for this strain.
Currently, the resistance mechanism and the
genetic background for it is not known. Close
attention should be paid to strains with similar
phenotypes/resistance mechanisms as they
may be emerging in Europe.
The testing and interpretation of results for the 
ESBL- and carbapenemase-producing strains 
appeared not to cause difficulties for any of the 
participating laboratories. As for the S-12.4 
which exhibited cefoxitin resistance and 
consequently fell into the category of AmpC-
phenotype, indeed also was an unusual 
phenotype. In general, when observing 
antimicrobial resistance profiles that present 
unexpected resistance to extended spectrum 
cephalosporins or carbapenems, laboratories 
should be alert and perform relevant retesting to 
confirm the phenotype and may also consider to 
forward the strain for reference testing at the 
EURL-AR. 
Even if no acceptance limit has been defined for 
this component of the EQAS, the overall result 
appears satisfactory.  
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4.2 Campylobacter trial 
For the Campylobacter component of this year’s 
EQAS, 30 laboratories submitted results leading 
to an overall percentage of correct AST results at 
99.3%. The performance varied from no 
deviations up to 10.4% deviations, with 29 
laboratories performing satisfactorily according 
to the established acceptance range.  
It appears that the level of deviations for the 
overall AST result is similar to the EQAS 2016, 
and in fact no deviations were observed in the 
results obtained from testing the internal control 
strain (Figure 2).  
One laboratory (#40) obtained deviation levels 
above 5%. For this laboratory, however, the 
values obtained for the QC-strain did not indicate 
methodical issues to be the reason for the 
obtained deviations. The EURL-AR has been in 
contact with this laboratory to offer assistance in 
identifying the possible cause of this 
unsatisfactory performance and to improve the 
quality of results. Of the five obtained deviations 
that caused the 10.4% deviation level, three 
were related to one strain (C-12.7) caused by 
incorrect categorisations as ‘resistant’ and 
indicates switch of strains may have happened. 
The laboratory did not store strain C-12.7 and 
communicated that further follow-up has not 
been performed, i.e. the cause of the deviations 
has currently not been identified. 
All participating laboratories except two (#4 and 
#42) uploaded data from tests performed on the 
C. jejuni reference strain and the proportion of
results within the QC intervals was 96.3%.
All five values outside the QC intervals were one 
step below or above the QC-limits. It is 
suggested that these values are monitored over 
time to ensure that the tests render a reliable 
result for the particular antimicrobial. 
In 2016, all laboratories obtained acceptable 
deviation levels for the AST results and therefore 
no follow-up is relevant.  
4.3 Genotypic characterisation 
The focus on genotypic characterization of 
microorganisms is increasing in the EU and 
worldwide. In EU, communication is ongoing to 
improve laboratory detection and confirmation of 
ESBL-, AmpC-, and carbapenemase-producing 
Enterobacteriaceae and also to identify the 
genetic mechanism conferring the resistance. 
The optional genotypic characterisation is a 
supplementary component of this EQAS and 
should therefore be seen as an important 
possibility for the NRL-AR’s to introduce or 
improve these methods in the laboratory. This 
year, twelve laboratories participated in the 
optional EQAS component and even though no 
acceptance limit has been defined, the 97% 
correct results (N=207) appears to be a 
satisfactory result.  
5. Conclusions
The goal of the EURL-AR EQAS is to have all 
participating NRLs performing antimicrobial 
susceptibility testing of Salmonella and 
Campylobacter with a deviation level below 5%. 
Again this year, this goal was reached for 
Salmonella and seems within reach for 
Campylobacter.  
Compared to the EQAS 2016, the performance 
of the NRL’s in 2017 appears to be at the same 
high level for Salmonella AST’s (99.3% in 2017 
and 98.9% in 2016) as well as for Campylobacter 
(99.3% in 2017 and 99.6% in 2016)  (Figure 2). 
One outlier for the Campylobacter AST obtained 
10.4% deviations and has been contacted to 
follow-up on the identification of the possible 
cause of this unsatisfactory performance with the 
purpose of improving the quality of results. 
The test covering the identification of the 
phenotype of Salmonella test strains producing 
beta-lactamases of the ESBL-, AmpC, and 
17 
carbapenemase-type caused rendered seven 
deviations (97.2% correct categorisations). All 
deviations were related to an unusual AmpC-
phenotype which was curiously susceptible to 
ampicillin. This is a priority area within the EURL-
AR activities, and the focus on identifying AmpC-
, ESBL-, and carbapenemase producing 
organisms – also those with unusual phenotypes 
– is encouraged.
Twelve NRLs participated in the EQAS
component consisting of genotypic testing of 
ESBL-, AmpC- and carbapenemase-producing 
Enterobacteriaceae presenting satisfactory 
results.  
Finally, the EURL-AR is open to suggestions to 
improve future EQAS trials and invites the entire 
network to contribute with ideas for training 
courses and specific focus areas to expand the 
network’s knowledge in antimicrobial resistance. 
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EQAS 2017 FOR SALMONELLA, CAMPYLOBACTER AND OPTIONAL GENOTYPIC 
CHARACTERISATION  
The EURL-AR announces the launch of another EQAS, thus providing the opportunity for 
proficiency testing which is considered an essential tool for the generation of reliable laboratory 
results of consistently good quality. 
This EQAS consists of antimicrobial susceptibility testing of eight Salmonella isolates and eight 
Campylobacter isolates. Additionally, quality control (QC) strains E. coli ATCC 25922 (CCM 
3954) and C. jejuni ATCC 33560 (CCM 6214) will be distributed to new participants.  
It is the recipients’ responsibility to comply with national legislation, rules and regulation regarding 
the correct use and handling of the provided strains and to possess the proper equipment and 
protocols to handle these strains. 
This EQAS is specifically for NRL’s on antimicrobial resistance (NRL-AR). Laboratories 
designated to be NRL-AR do not need to sign up to participate but are automatically regarded as 
participants. You may contact the EQAS-Coordinator if you wish to inform of changes in relation to 
your level of participation in compared to previous years. The EURL-AR will be able to cover the 
expenses for one parcel, only, per EU Member State. Therefore, countries with more than one 
laboratory registered on the EURL-AR contact-list will be contacted directly to confirm which 
laboratory will be included for participation free of charge.  
The invitation to participate in the proficiency test is extended to additional participants besides 
official NRLs and to participants from laboratories which are involved in the network but are not 
designated NRLs (cost for participation will be 100 EUR). 
TO AVOID DELAY IN SHIPPING THE ISOLATES TO YOUR LABORATORY 
The content of the parcel is “UN3373, Biological Substance Category B”: Eight Salmonella strains, 
eight Campylobacter and for new participants also the QC strains mentioned above. Please provide 
the EQAS coordinator with documents or other information that can simplify customs procedures 
(e.g. specific text that should be written on the proforma invoice). To avoid delays, we kindly ask 
you to send this information already at this stage.  
TIMELINE FOR RESULTS TO BE RETURNED TO THE NATIONAL FOOD INSTITUTE 
Shipment of isolates and protocol: The isolates will be shipped in October 2017. The protocol for 
this proficiency test will be available for download from the website (www.eurl-ar.eu).  
Submission of results: Results must be submitted to the National Food Institute no later than 
December 18th 2017 via the password-protected website.  
Upon reaching the deadline, each participating laboratory is kindly asked to enter the password-
protected website once again to download an automatically generated evaluation report. 
EQAS report: A report summarising and comparing results from all participants will be issued. In 
the report, laboratories will be presented coded, which ensures full anonymity. The EURL-AR and 
the EU Commission, only, will have access to un-coded results. The report will be publicly 
available. 
Appendix 1, page 1 of 2
EU Reference Laboratory for Antimicrobial Resistance 
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Next EQAS: The next EURL-AR EQAS that we will have is on isolation of ESBL- and AmpC-
producing E. coli from caeca and meat samples which is expected to be carried out in November 
2017 and for antimicrobial susceptibility testing, the next EQAS will be the testing of E. coli, 
staphylococci and enterococci which will be carried out in June 2018.  
Please contact me if you have comments or questions regarding the EQAS. 
Sincerely, 
Susanne Karlsmose Pedersen 
EURL-AR EQAS-Coordinator 
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Participant list
Salmonella Campylobacter Genotypic characterisation Institute  Country
X X X Austrian Agency for Health and Food Safety Austria
X X X Institute of Public Health Belgium
X X - National Diagnostic and Research Veterinary Institute Bulgaria
X X - Croatian Veterinary Institut Croatia
X X - Veterinary Services Cyprus
X X - State Veterinary Institute Praha Czech Republic
X* X* X DTU National Food Institute Denmark
X X - Danish Veterinary and Food Administration, DVFA Denmark
X X - Estonian Veterinary and Food Laboratory Estonia
X X - Finnish Food Safety Authority EVIRA Finland
X - - Agence nationale de sécurité sanitaire ANSES - Fougères LERMVD France
- X - Agence nationale de sécurité sanitaire ANSES - Ploufragan - LERAP France
X X X Federal Institute for Risk Assessment Germany
X X - Veterinary Laboratory of Chalkis Greece
X X - Central Agricultural Office Veterinary Diagnostic Directorate Hungary
X X - University of Iceland Iceland
X X X Central Veterinary Research Laboratory Ireland
X X X Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana Italy
X X X Institute of Food Safety, Animal Health and Enviroment "BIOR" Latvia
X X - National Food and Veterinary Risk Assessment Institute Lithuania
X X - Laboratoire national de Santé Luxembourg
X X - Public Health Laboratory Malta
X X X Central Veterinary Institute of Wageningen UR Netherlands
X* X* - Food and Consumer Product Safety Authority (VWA) Netherlands
X X X Veterinærinstituttet Norway
X X - National Veterinary Research Institute Poland
X X - Laboratorio National de Investigacáo Veterinaria Portugal
X* X* - Institute for Hygiene and Veterinary Public Health Romania
X X X Institute for Diagnosis and Animal Health Romania
X X - State Veterinary and Food Institute  (SVFI) Slovakia 
X X - National Veterinary Institute Slovenia
X X X Laboratorio Central de Sanidad, Animal de Algete Spain
X* X* - VISAVET Health Surveillance Center, Complutense University Spain
X X X National Veterinary Institute, SVA Sweden
X X - Vetsuisse Faculty Bern, Institute of Veterinary Bacteriology Switzerland
X* X* X* Public Health England United Kingdom
X X - Animal Plant Health Agency United Kingdom
Designated NRL-AR by the compentent authority of the member state
Non-NRL-AR enrolled by the EURL-AR
Not a Member State of the EU
* Submitted results were not included in the current report (allows for one dataset per country, only)
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Reference values (MIC-value and interpretation) - Salmonella 
Ampicillin Azithromycin Cefepime Cefotaxime Cefotaxime/clav F:F/C Cefoxitin Ceftazidime Ceftazidime/clav T:T/C Chloramphenicol Ciprofloxacin Colistin Ertapenem
AMP AZI FEP FOT F/C ratio FOX TAZ T/C ratio CHL CIP COL
EURL S-12.1 >64 RESIST >64 RESIST 32 NA >64 RESIST >64 <8 >64 RESIST >128 RESIST >128 <8 >128 RESIST >8 RESIST <=1 SUSC 1 RESIST
EURL S-12.2 >64 RESIST 8 SUSC 2 NA 16 RESIST 0.06 >=8 4 SUSC 1 SUSC 0.25 <8 <=8 SUSC 0.5 RESIST <=1 SUSC <=0.015 SUSC
EURL S-12.3 >64 RESIST 4 SUSC >32 NA >64 RESIST 0.12 >=8 4 SUSC 8 RESIST 0.5 >=8 <=8 SUSC 0.12 RESIST <=1 SUSC 0.03 SUSC
EURL S-12.4 2 SUSC 8 SUSC 0.12 NA 1 RESIST 0.5 <8 32 RESIST 8 RESIST 4 <8 <=8 SUSC 0.03 SUSC <=1 SUSC <=0.015 SUSC
EURL S-12.5 2 SUSC 4 SUSC <=0.25 SUSC <=0.5 SUSC <=8 SUSC 0.03 SUSC 4 RESIST
EURL S-12.6 >64 RESIST 8 SUSC <=0.25 SUSC 1 SUSC <=8 SUSC >8 RESIST <=1 SUSC
EURL S-12.7 >64 RESIST >64 RESIST 8 NA 32 RESIST 0.12 >=8 8 SUSC 2 SUSC 0.25 >=8 >128 RESIST 0.03 SUSC <=1 SUSC <=0.015 SUSC
EURL S-12.8 >64 RESIST >64 RESIST >32 NA >64 RESIST >64 <8 >64 RESIST >128 RESIST >128 <8 64 RESIST >8 RESIST <=1 SUSC >2 RESIST
Gentamicin IMIPENEM MEROPENEM Nalidixic acid Sulfamethoxazole TEMOCILLIN Tetracycline TIGECYCLINE Trimethoprim
GEN IMI MER NAL SMX TRM TETRA TGC TMP ESBL-category Relevant genes
EURL S-12.1 1 SUSC 2 RESIST 1 RESIST >128 RESIST >1024 RESIST 128 RESIST >64 RESIST 0.5 SUSC >32 RESIST
EURL S-12.2 <=0.5 SUSC 0.25 SUSC <=0.03 SUSC >128 RESIST 32 SUSC 4 SUSC 64 RESIST <=0.25 SUSC <=0.25 SUSC
EURL S-12.3 <=0.5 SUSC 0.25 SUSC 0.06 SUSC >128 RESIST >1024 RESIST 8 SUSC >64 RESIST 0.5 SUSC >32 RESIST
EURL S-12.4 <=0.5 SUSC 0.25 SUSC 0.06 SUSC <=4 SUSC 64 SUSC >128 RESIST 4 SUSC 0.5 SUSC 0.5 SUSC
EURL S-12.5 <=0.5 SUSC 0.06 SUSC 8 SUSC 64 SUSC 4 SUSC <=0.25 SUSC 0.5 SUSC
EURL S-12.6 16 RESIST <=0.03 SUSC >128 RESIST >1024 RESIST 64 RESIST 0.5 SUSC <=0.25 SUSC
EURL S-12.7 <=0.5 SUSC 0.25 SUSC 0.06 SUSC <=4 SUSC >1024 RESIST 8 SUSC >64 RESIST 1 SUSC >32 RESIST
EURL S-12.8 >32 RESIST 8 RESIST 16 RESIST >128 RESIST >1024 RESIST 128 RESIST 4 SUSC 0.5 SUSC 0.5 SUSC
Resistant
CTX M-14
NDM-1
CTX-M15 
DHA-1 
OXA-1 
OXA-9
OXA-10
TEM-1B
carbapenemase-phenotype
ESBL-phenotype
carbapenemase-phenotype
ESBL-phenotype
none
none
AmpC
ESBL-phenotype CTX M-14b
unknown
NDM-1
CMY-16
CTX M-9
TEM-1B
Appendix 3b, page 1 of 1Reference values (MIC-value and interpretation) - Campylobacter 
Ciprofloxacin Erythromycin Gentamicin Nalidixic acid Streptomycin Tetracycline
Species Code CIP ERY GEN NAL STR TET
C. jejuni EURL C-12.1 <=0.12 SUSC  <=  1 SUSC 0.5 SUSC 8 SUSC 2 SUSC  <=   0.5 SUSC
C. jejuni EURL C-12.2 >16 RESIST 128 RESIST 0.5 SUSC >64 RESIST >16 RESIST 64 RESIST
C. jejuni EURL C-12.3 <=0.12 SUSC  <=  1 SUSC 0.5 SUSC 4 SUSC >16 RESIST 8 RESIST
C. jejuni EURL C-12.4 8 RESIST  <=  1 SUSC <=0.12 SUSC 64 RESIST 0.5 SUSC 64 RESIST
C. jejuni EURL C-12.5 4 RESIST  <=  1 SUSC 0.5 SUSC 64 RESIST >16 RESIST 64 RESIST
C. coli EURL C-12.6 16 RESIST  <=  1 SUSC 0.5 SUSC >64 RESIST 2 SUSC >64 RESIST
C. coli EURL C-12.7 <=0.12 SUSC  <=  1 SUSC 0.5 SUSC 4 SUSC 2 SUSC  <=   0.5 SUSC
C. jejuni EURL C-12.8 8 RESIST  <=  1 SUSC 0.25 SUSC >64 RESIST 1 SUSC 64 RESIST
Resistant
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EURL-AR External Quality Assurance System 2017    
- Salmonella, Campylobacter and optional genotypic characterisation  
 
Id: «Lab_no_» 
«Name» 
«Institute__»  
«Country» 
Kgs. Lyngby, October 2017 
 
Dear «Name», 
 
Please find enclosed the bacterial strains for the EURL-AR EQAS 2017: eight Salmonella spp. 
and eight Campylobacter spp. Upon arrival to your laboratory, the strains should be stored in a 
dark place at 4°C for stabs, and in a dark and cool place for freeze-dried strains. Charcoal swabs 
must be subcultured upon arrival.  
 
On the EURL-AR-website (www.eurl-ar.eu) the following documents relevant for this EURL-AR 
EQAS are available: 
- Protocol for antimicrobial susceptibility testing of Salmonella and Campylobacter and test 
forms for reporting results  
- Instructions for Opening and Reviving Lyophilised Cultures 
- Subculture and Maintenance of Quality Control Strains 
 
We ask you to test these Salmonella and Campylobacter strains for antimicrobial susceptibility. 
Detailed description of the procedures to follow for antimicrobial susceptibility testing, for 
optional genotypic characterization and for entering your results into the interactive web database 
can be found in the protocol. For accessing the database, you need this username and password. 
 
 
Your username: «Username» 
 
Your password: «Password» 
 
Please keep this document 
  Your username and password will not appear in other documents 
 
 
Results should be submitted to the database no later than 18th December 2017. 
 
Please acknowledge receipt of this parcel immediately upon arrival (to suska@food.dtu.dk).  
Do not hesitate to contact me for further information. 
 
Yours sincerely, 
 
Susanne Karlsmose Pedersen 
EURL-AR EQAS-Coordinator 
EU Reference Laboratory for Antimicrobial Resistance 
External Quality Assurance System (EQAS) 2017 
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PROTOCOL 
For antimicrobial susceptibility testing of Salmonella, Campylobacter and optional 
genotypic characterisation of AmpC-, ESBL- and carbapenemase-producing test strains 
1 INTRODUCTION  ................................................................................................................... 1 
2 OBJECTIVES  .......................................................................................................................... 2 
3 OUTLINE OF THE SALM/CAMP EQAS 2017  .................................................................. 2 
3.1    Shipping, receipt and storage of strains  .............................................................. 2 
3.2    QC reference strains ............................................................................................. 2 
3.3    Antimicrobial susceptibility testing  ..................................................................... 3 
3.4    Optional genotypic characterisation  .................................................................... 5 
4 REPORTING OF RESULTS AND EVALUATION  ........................................................... 6 
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE .............................  6 
APPENDIX  ........................................................................................................................................ 8 
1 INTRODUCTION 
The organisation and implementation of an External Quality Assurance System (EQAS) on 
antimicrobial susceptibility testing (AST) of Salmonella and Campylobacter is among the tasks of 
the EU Reference Laboratory for Antimicrobial Resistance (EURL-AR). The 
Salmonella/Campylobacter EQAS 2017 will include AST of eight Salmonella and Campylobacter 
strains and AST of reference strains E. coli ATCC 25922 (CCM 3954) and C. jejuni ATCC 33560 
(CCM 6214).  
The reference strains are included in the parcel only for new participants of the EQAS who did not 
receive them previously. The reference strains are original CERTIFIED cultures provided free of 
charge, and should be used for future internal quality control for antimicrobial susceptibility testing 
in your laboratory. The reference strains will not be included in the years to come. Therefore, please 
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take proper care of these strains. Handle and maintain them as suggested in the manual ‘Subculture 
and Maintenance of QC Strains’ available on the EURL-AR website (see www.eurl-ar.eu).  
Various aspects of the proficiency test scheme may from time to time be subcontracted. When 
subcontracting occurs it is placed with a competent subcontractor and the National Food Institute is 
responsible to the scheme participants for the subcontractor’s work. 
2 OBJECTIVES 
This EQAS aims to support laboratories to assess and, if necessary, to improve the quality of results 
obtained by AST of pathogens of food- and animal-origin, with special regard to Salmonella and 
Campylobacter. Further objectives are to evaluate and improve the comparability of surveillance 
data on antimicrobial susceptibility of Salmonella and Campylobacter reported to EFSA by 
different laboratories. 
3 OUTLINE OF THE SALM/CAMP EQAS 2017 
3.1    Shipping, receipt and storage of strains 
In October 2017, the National Reference Laboratories for Antimicrobial Resistance (NRL-AR) will 
receive a parcel containing eight Salmonella and Campylobacter strains from the National Food 
Institute. This parcel will also contain reference strains, but only for participants who did not 
receive them previously.  
All strains belong to UN3373, Biological substance, category B. Extended spectrum beta-lactamase 
(ESBL)-producing strains as well as carbapenemase producing strains are included in the selected 
material and are part of the optional EQAS-item, consisting of characterization of genes conferring 
ESBL- or carbapenemase production. It is the recipients’ responsibility to comply with national 
legislation, rules and regulation regarding the correct use and handling of the provided strains and to 
possess the proper equipment and protocols to handle these strains. 
The reference strains are shipped lyophilised, the Campylobacter test strains are shipped as a 
charcoal swabs and the Salmonella test strains are stab cultures. On arrival, the stab cultures and the 
charcoal swabs must be subcultured, and all cultures should be adequately stored until testing. A 
suggested procedure for reconstitution of the lyophilised reference strains is presented below. 
3.2 QC reference strains  
For a suggested procedure for reconstitution of the lyophilised, please refer to the document 
‘Instructions for opening and reviving lyophilised cultures’ on the EURL-AR-website (see 
www.eurl-ar.eu). 
Note that, for the testing of the E. coli ATCC25922 reference strain, the two compounds, 
sulfamethoxazole and sulfisoxazole, are regarded as comparable, i.e. the obtained MIC-value from 
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the testing of sulfamethoxazole will be evaluated against the acceptance range listed in CLSI M100 
for sulfisoxazole.  
 
3.3 Antimicrobial susceptibility testing 
The strains should be tested for susceptibility to the antimicrobials listed in Tables 1, 2 and 3, using 
the method implemented in your laboratory for performing monitoring for EFSA and applying the 
interpretative criteria listed below. 
Participants should perform minimum inhibitory concentration (MIC) determination using the 
methods stated in the EC regulation EC 652/2013. For interpretation of the results, use the cut-off 
values listed in Tables 1, 2 and 3 (except where indicated) represent the current epidemiological 
cut-off values developed by EUCAST (www.eucast.org), and allow categorisation of bacterial 
isolates into two categories; resistant or susceptible. A categorisation as intermediate is not 
accepted.  
As the current regulation and recommendations focus on MIC testing only, results obtained by disk 
diffusion cannot be submitted. 
3.3.1 Salmonella. 
The interpretative criteria that should be applied for categorizing the Salmonella test strain as 
resistant or susceptible are those listed in Tables 1 and 2.  
Table 1: Antimicrobials recommended for AST of Salmonella spp. and interpretative criteria according to 
table 1 in EC regulation 652/2013 
Antimicrobial MIC (µg/mL) (R>) 
Ampicillin (AMP) 8 
Azithromycin (AZI) 16* 
Cefotaxime (FOT) 0.5 
Ceftazidime (TAZ) 2 
Chloramphenicol (CHL) 16 
Ciprofloxacin (CIP) 0.064 
Colistin (COL) 2 
Gentamicin (GEN) 2 
Meropenem (MERO) 0.125 
Nalidixic acid (NAL) 16 
Sulfonamides (SMX) 256** 
Tetracycline (TET) 8 
Tigecycline (TGC) 1*** 
Trimethoprim (TMP) 2 
* Tentative value 
** CLSI M100 Table 2A 
*** Data from EUCAST is available for S. Enteritidis, S. Typhimurium, S. Typhi and S. Paratyphi (for the 
purpose of this proficiency test, the ECOFF at 1 is applied) 
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Table 2: Antimicrobials recommended for additional AST of Salmonella spp. resistant to cefotaxime, 
ceftazidime or meropenem and interpretative criteria according to table 4 in EC regulation 652/2013 
Antimicrobial MIC (µg/mL) (R>) 
Cefepime, FEP Not available* 
Cefotaxime, FOT 0.5 
Cefotaxime + clavulanic acid (F/C) Not applicable 
Cefoxitin, FOX 8 
Ceftazidime, TAZ 2 
Ceftazidime+ clavulanic acid (T/C) Not applicable 
Ertapenem, ETP 0.06 
Imipenem, IMI 1 
Meropenem, MERO 0.125 
Temocillin, TRM 32** 
* Participants are requested to upload the MIC value obtained without selecting an interpretation 
** Tentative value 
 
Plasmid-mediated quinolone resistance  
When performing antimicrobial susceptibility testing of the Salmonella test strains, the 
interpretative criteria listed in Table 1 for results obtained by MIC-determination should allow 
detection of plasmid-mediated quinolone resistant test strains.  
Beta-lactam- and carbapenem resistance  
Confirmatory tests for ESBL production are mandatory on all strains resistant to cefotaxime 
(FOT), ceftazidime (TAZ) and/or meropenem and should be performed by testing the second panel 
of antimicrobials (Table 2 in this document corresponding to Table 4 in Commission Implementing 
Decision 2013/652/EU). 
Confirmatory test for AmpC-, ESBL- and carbapenemase production requires use of both 
cefotaxime (FOT) and ceftazidime (TAZ) alone and in combination with a β-lactamase inhibitor 
(clavulanic acid). Synergy is defined either as i) a ≥ 3 twofold concentration decrease in an MIC for 
either antimicrobial agent tested in combination with clavulanic acid vs. the MIC of the agent when 
tested alone (MIC FOT : FOT/Cl or TAZ : TAZ/Cl ratio ≥ 8) (CLSI M100 Table 3A, Tests for 
ESBLs). The presence of synergy indicates ESBL production.  
Confirmatory test for carbapenemase production requires the testing of meropenem (MERO).  
Detection of AmpC-type beta-lactamases can be performed by testing the bacterium for 
susceptibility to cefoxitin (FOX). Resistance to FOX could indicate the presence of an AmpC-type 
beta-lactamase. 
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The classification of the phenotypic results should be based on the most recent EFSA 
recommendations (available in The European Union summary report on antimicrobial resistance in 
zoonotic and indicator bacteria from humans, animals and food in 2015, EFSA Journal 
2017;15(2):4694,212 pp. (page 43), and in the appendix to this protocol). It is important to notice 
that two cut-off values apply for cefotaxime and ceftazidime: the EUCAST cut-off values 
(ECOFFs: FOT>0.5 and TAZ>2), which are those used to define R/S, and the screening cut-off 
values (FOT>1 and TAZ>1), which are those applied to categorise bacterial phenotypes as ESBL, 
AmpC, carbapenemase, etc. based on panel 2 results (see Appendix).  
3.3.2 Campylobacter 
For AST of Campylobacter, MIC methods should be applied, i.e. broth or agar dilution methods 
using incubation at 36-37ºC for 48 hours or 42ºC for 24 hours.  
Table 3: Antimicrobials recommended for AST of Campylobacter jejuni and C. coli and 
interpretative criteria according to table 1 in EC regulation 652/2013 
Antimicrobial C. jejuni C. coli
MIC (µg/mL) (R>) MIC (µg/mL) (R>) 
Ciprofloxacin (CIP) 0.5 0.5 
Erythromycin (ERY) 4 8 
Gentamicin (GEN) 2 2 
Nalidixic acid (NAL) 16 16 
Streptomycin (STR) 4 4 
Tetracycline (TET) 1 2 
Identification of Campylobacter species 
Species identification of the Campylobacter test strains must be performed by the NRLs using in-
house methods or adopting the protocol available on the EURL-AR website under: http://eurl-
ar.eu/233-protocols.htm. 
3.4 Optional genotypic characterisation 
For the optional genotypic characterisation of the AmpC-, ESBL- or carbepenemase producing 
Salmonella test strains, the requested results are the genes encoding AmpC-, ESBL- or 
carbepenemase –production. AmpC-, ESBL- or carbapenemase types included in the test are the 
following: ACC, ACT, CARB, CMY, CTX-M, DHA, FOX, GES, IMP, KPC, MOX, NDM, OXA, 
PER, SCO, SHV, TEM, VEB, and VIM. The database lists the relevant variants of each type.   
When uploading the results in the database, the identified genes will be evaluated against the 
expected results. The results will be evaluated on the detected type (ACC-, ACT-, CARB-, etc.) as 
well as the variant identified.  
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The method used for the genotypic characterisation should be your laboratory’s routine method. 
The expected results listed in the database are those obtained by the EURL-AR.  
4 REPORTING OF RESULTS AND EVALUATION 
Test forms are available for recording your results before you enter them into the interactive web 
database.  
We recommend reading carefully the description reported in paragraph 5 before entering your 
results in the web database.  Results must be submitted no later than December 18th 2017. After 
the deadline when all participants have uploaded results, you will be able to login to the database 
once again, and to view and print an automatically generated report evaluating your results. Results 
in agreement with the expected interpretation are categorised as ‘correct’, while results deviating 
from the expected interpretation are categorised as ‘incorrect’. 
If you experience difficulties in entering your results, please contact us directly.  
All results will be summarized in a report which will be publicly available. The data in the report 
will be presented with laboratory codes. A laboratory code is known to the individual laboratory, 
whereas the complete list of laboratories and their codes is confidential and known only to the 
EURL-AR and the EU Commission. All conclusions will be public. 
If you have questions, please do not hesitate to contact the EQAS Coordinator: 
 
Susanne Karlsmose Pedersen 
National Food Institute,  
Technical University of Denmark 
Kemitorvet, Building 204, DK-2800 Lyngby 
Denmark 
Tel: +45 3588 6601 
E-mail: suska@food.dtu.dk 
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE 
Please read carefully this paragraph before entering the web page. 
Remember that you need by your side the completed test forms.  
Enter the EURL-AR EQAS start web page (http://eurl-ar.food.dtu.dk), write your username and 
password (lower-case) and press enter. Your username and password are indicated in the letter 
following your strains. Do not hesitate to contact us if you experience problems with the login. 
You can browse back and forth by using the Home or back keys, but please remember to save your 
inputs before. 
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Click on either “Salmonella test results” or “Campylobacter test results” for input of test results. 
Click on "Start of Data Entry - Methods” 
In the next page, you navigate among fields with the Tab-key and the mouse.  
Complete the fields related to the method used for antimicrobial susceptibility testing and the brand 
of MIC trays, etc.  
When submitting Campylobacter results, fill in the incubation conditions applied for susceptibility 
testing of Campylobacter – 36°C/48h or 42°C/24h. 
Click on "save and go to next page” 
In the data entry pages, you enter the species (for Campylobacter only), the obtained MIC-value 
and the interpretation (R, resistant or S, susceptible) for each Salmonella and Campylobacter strain. 
For Salmonella, remember to also report the results for the ESBL detection tests. 
If you did not test for susceptibility to a given antimicrobial, please leave the field empty. 
Click on "save and go to next page" 
When uploading data on the reference strains, please enter MIC values in µg/ml. Remember to use 
the operator keys to show symbols like “equal to”, etc. 
Click on “save“. 
Review the input pages by browsing through them and make corrections if necessary. Remember to 
save a page if you make corrections. If you press home a page without saving changes, you will see 
an error screen. In this case, click on “save“ to save your results, browse back to the page and then 
continue. 
Please complete the evaluation form. 
Before approving your input, please be sure that you have filled in all the relevant fields as  YOU 
CAN ONLY APPROVE ONCE!  The approval blocks your data entry in the interactive database. 
If you have performed the optional genotypic characterisation: 
Click on “Gene test” and follow the description in the database for upload of the results of the 
optional genotypic characterization. Approve your input. Be sure that you have filled in all the 
results before approval. The approval blocks your data entry in the interactive database, but allows 
you to see the submitted results. 
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APPENDIX 
Criteria for interpretation of Salmonella, panel 2 results 
Please refer to: EFSA (European Food Safety Authority) and ECDC (European Centre for Disease 
Prevention and Control), 2017. The European Union summary report on antimicrobial resistance in 
zoonotic and indicator bacteria from humans, animals and food in 2015. EFSA Journal 
2017;15(2):4694, 212 pp. doi:10.2903/j.efsa.2017.4694 (page 43). 
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Salmonella, Campylobacter and genetic characterisation 
 
TEST FORMS 
   
 
 
Name:       
 
Name of laboratory:       
 
Name of institute:       
 
City:       
 
Country:       
 
E-mail:       
 
Fax:       
 
 
Comments:       
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TEST FORM                                                            
 
Does your laboratory have an accreditation for performing Salmonella AST?   Yes     No 
 
Which method did you use for antimicrobial susceptibility testing of Salmonella in this EQAS: 
  Broth microdilution    
  Agar dilution 
 
 Brand of microbroth plates/agar:        
 Incubation conditions:      °C/     h 
 
How many Salmonella isolates does your laboratory annually isolate:       
 
How many Salmonella isolates does your laboratory annually test for antimicrobial susceptibility by 
a MIC method:       
 
Which method was followed for the preparation of the inoculum (please describe) 
 Which standard was followed (TREK, CLSI…)       
 Which solvent was used for the preparation of the 0.5 McFarland solution (water, saline)       
 Please describe in detail how you prepared the dilution of the inoculum (including the volume in 
final MH-dilution and intended dilution level; e.g. diluted 1:1000 by adding 10µl of 0.5 
McFarland solution in 10ml MH broth, for an expected inoculum of 1*105 CFU/ml)       
 
Comments or additional information:       
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TEST FORM          
 
Does your laboratory have an accreditation for Campylobacter AST?  Yes     No 
 
 
Incubation conditions:     36-37ºC / 48h   42ºC / 24h 
 
Method used for antimicrobial susceptibility testing of Campylobacter in this EQAS: 
 Broth microdilution 
 Agardilution 
 
Brand of microbroth plates/agar:       
 
How many Campylobacter isolates does your laboratory annually isolate:       
How many Campylobacter isolates does your laboratory annually susceptibility test:       
 
Which method was followed for the preparation of the inoculum (please describe) 
 Which standard was followed (TREK, CLSI…)       
 Which solvent was used for the preparation of the 0.5 McFarland solution (water, saline)       
 Please describe in detail how you prepared the dilution of the inoculum (including the volume in 
final MH-dilution and intended dilution level; e.g. diluted 1:1000 by adding 10µl of 0.5 
McFarland solution in 10ml MH broth, for an expected inoculum of 1*105 CFU/ml)       
 
Comments or additional information:       
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TEST FORM                            
 
Strain Antimicrobial  Results and interpretation 
 / > MIC-value (μg/ml) S / R 
Salmonella EURL S. 12.1 
Ampicillin, AMP                         
Azithromycin, AZI                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
 
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be 
included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or 
carbapenemase production. See further description in the protocol section ‘3.3.1 Salmonella’.                   
 
Strain Antimicrobial  Results and interpretation 
 / > MIC-value (μg/ml) S / R 
Salmonella 
EURL S. 12.1 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive Carbapenemase 
 
 Other phenotype 
 Susceptible 
 
Comments (include optional genotype or other results):       
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TEST FORM                            
 
Strain Antimicrobial  Results and interpretation 
 / > MIC-value (μg/ml) S / R 
Salmonella EURL S. 12.2 
Ampicillin, AMP                         
Azithromycin, AZI                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
 
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be 
included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or 
carbapenemase production. See further description in the protocol section ‘3.3.1 Salmonella’.                   
 
Strain Antimicrobial  Results and interpretation 
 / > MIC-value (μg/ml) S / R 
Salmonella 
EURL S. 12.2 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive Carbapenemase 
 
 Other phenotype 
 Susceptible 
 
Comments (include optional genotype or other results):       
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TEST FORM                            
 
Strain Antimicrobial  Results and interpretation 
 / > MIC-value (μg/ml) S / R 
Salmonella EURL S. 12.3 
Ampicillin, AMP                         
Azithromycin, AZI                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
 
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be 
included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or 
carbapenemase production. See further description in the protocol section ‘3.3.1 Salmonella’.                   
 
Strain Antimicrobial  Results and interpretation 
 / > MIC-value (μg/ml) S / R 
Salmonella 
EURL S. 12.3 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive Carbapenemase 
 
 Other phenotype 
 Susceptible 
 
Comments (include optional genotype or other results):       
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TEST FORM                            
 
Strain Antimicrobial  Results and interpretation 
 / > MIC-value (μg/ml) S / R 
Salmonella EURL S. 12.4 
Ampicillin, AMP                         
Azithromycin, AZI                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
 
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be 
included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or 
carbapenemase production. See further description in the protocol section ‘3.3.1 Salmonella’.                   
 
Strain Antimicrobial  Results and interpretation 
 / > MIC-value (μg/ml) S / R 
Salmonella 
EURL S. 12.4 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive Carbapenemase 
 
 Other phenotype 
 Susceptible 
 
Comments (include optional genotype or other results):       
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TEST FORM                            
 
Strain Antimicrobial  Results and interpretation 
 / > MIC-value (μg/ml) S / R 
Salmonella EURL S. 12.5 
Ampicillin, AMP                         
Azithromycin, AZI                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
 
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be 
included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or 
carbapenemase production. See further description in the protocol section ‘3.3.1 Salmonella’.                   
 
Strain Antimicrobial  Results and interpretation 
 / > MIC-value (μg/ml) S / R 
Salmonella 
EURL S. 12.5 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive Carbapenemase 
 
 Other phenotype 
 Susceptible 
 
Comments (include optional genotype or other results):       
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TEST FORM                            
 
Strain Antimicrobial  Results and interpretation 
 / > MIC-value (μg/ml) S / R 
Salmonella EURL S. 12.6 
Ampicillin, AMP                         
Azithromycin, AZI                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
 
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be 
included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or 
carbapenemase production. See further description in the protocol section ‘3.3.1 Salmonella’.                   
 
Strain Antimicrobial  Results and interpretation 
 / > MIC-value (μg/ml) S / R 
Salmonella 
EURL S. 12.6 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive Carbapenemase 
 
 Other phenotype 
 Susceptible 
 
Comments (include optional genotype or other results):       
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TEST FORM                            
 
Strain Antimicrobial  Results and interpretation 
 / > MIC-value (μg/ml) S / R 
Salmonella EURL S. 12.7 
Ampicillin, AMP                         
Azithromycin, AZI                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
 
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be 
included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or 
carbapenemase production. See further description in the protocol section ‘3.3.1 Salmonella’.                   
 
Strain Antimicrobial  Results and interpretation 
 / > MIC-value (μg/ml) S / R 
Salmonella 
EURL S. 12.7 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive Carbapenemase 
 
 Other phenotype 
 Susceptible 
 
Comments (include optional genotype or other results):       
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TEST FORM                            
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
Salmonella EURL S. 12.8 
Ampicillin, AMP                         
Azithromycin, AZI                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
 
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be 
included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or 
carbapenemase production. See further description in the protocol section ‘3.3.1 Salmonella’.                   
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
Salmonella 
EURL S. 12.8 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive Carbapenemase 
 
 Other phenotype 
 Susceptible 
 
Comments (include optional genotype or other results):       
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TEST FORM                                                            
 
Antimicrobial susceptibility testing of reference strain E. coli ATCC 25922 
 
 
 
Antimicrobial  
 
MIC-value (μg/ml) 
1st panel 
 
 
Ampicillin, AMP        
Azithromycin, AZI       
Cefotaxime, FOT       
Ceftazidime, TAZ       
Chloramphenicol, CHL       
Ciprofloxacin, CIP       
Colistin, COL       
Gentamicin, GEN       
Meropenem, MERO       
Nalidixic acid, NAL       
Sulfamethoxazole, SMX*       
Tetracycline, TET       
Tigecycline, TGC       
Trimethoprim, TMP       
2nd panel Cefepime, FEP       
Cefotaxime, FOT       
Cefotaxime + clavulanic acid (F/C)       
Cefoxitin, FOX       
Ceftazidime, TAZ       
Ceftazidime+ clavulanic acid (T/C)       
Ertapenem, ETP       
Imipenem, IMI       
Meropenem, MERO       
Temocillin, TRM       
* for the testing of the E. coli ATCC25922 reference strain, sulfamethoxazole and sulfisoxazole, are 
regarded as comparable, i.e. the obtained MIC-value from the testing of sulfamethoxazole will be evaluated 
against the acceptance range listed in CLSI M100 for sulfisoxazole (CLSI M100, Table 3). 
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TEST FORM                                                           
Strain Antimicrobial  Interpretation 
MIC-value (μg/ml) S / R 
Campylobacter 
EURL C-12.1 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C-12.2 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C-12.3 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C-12.4 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic acid             
Streptomycin             
Tetracycline             
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TEST FORM                                                            
Strain Antimicrobial  Interpretation 
MIC-value (μg/ml) S / R 
Campylobacter 
EURL C-12.5 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin   
Erythromycin   
Gentamicin   
Nalidixic acid   
Streptomycin   
Tetracycline   
Campylobacter 
EURL C-12.6 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin   
Erythromycin   
Gentamicin   
Nalidixic acid   
Streptomycin   
Tetracycline   
Campylobacter 
EURL C-12.7 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin   
Erythromycin   
Gentamicin   
Nalidixic acid   
Streptomycin   
Tetracycline   
Campylobacter 
EURL C-12.8 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin   
Erythromycin   
Gentamicin   
Nalidixic acid   
Streptomycin   
Tetracycline   
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TEST FORM                                                           
 
Susceptibility testing of Campylobacter jejuni reference strain ATCC 33560 
 
Strain 
 
 
 
Antimicrobial  
 
MIC-value (μg/ml) 
36 °C/48 hours 
 
42 °C/24 hours 
 
 
C. jejuni ATCC 33560 
 
Ciprofloxacin             
Erythromycin             
Nalidixic acid             
Tetracycline             
 
 
  
For Agar dilution: 
 
 Susceptibility testing of Campylobacter jejuni reference strain ATCC 33560 
 
Strain 
 
 
 
Antimicrobial  
 
MIC-value (μg/ml) 
 
C. jejuni ATCC 33560 
 
 
Ciprofloxacin       
Erythromycin        
Gentamicin       
Nalidixic acid        
Tetracycline       
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TEST FORM – genotypic characterisation                                    
 
Genotypic characterisation of the test strains 
 
Strain code:  
      
Method used:        
If PCR-methods, additional information should be given below 
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
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Strain code:  
      
Method used:        
If PCR-methods, additional information should be given below 
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Comments:       
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INSTRUCTIONS FOR OPENING AND REVIVING 
LYOPHILISED CULTURES 
Instructions adjusted from Czech Collection of Microorganisms (CCM) document ’Instructions for 
Opening and Reviving of Freeze-Dried Bacteria and Fungi’ available on http://www.sci.muni.cz.  
Lyophilised cultures are supplied in vacuum-sealed ampoules. Care should be taken in opening the 
ampoule. All instructions given below should be followed closely to ensure the safety of the person 
who opens the ampoule and to prevent contamination of the culture. 
a. Check the number of the culture on the label inside the ampoule
b. Make a file cut on the ampoule near the middle of the plug (see Figure 1)
c. Disinfect the ampoule with alcohol-dampened gauze or alcohol-dampened cotton wool from
just below the plug to the pointed end
d. Apply a red-hot glass rod to the file cut to crack the glass and allow air to enter slowly into
the ampoule
e. Remove the pointed end of the ampoule into disinfectant
f. Add about 0.3 ml appropriate broth to the dried suspension using a sterile Pasteur pipette
and mix carefully to avoid creating aerosols. Transfer the contents to one or more suitable
solid and /or liquid media
g. Incubate the inoculated medium at appropriate conditions for several days
h. Autoclave or disinfect effectively the used Pasteur pipette, the plug and all the remains of
the original ampoule before discarding
Notes:  
 Cultures should be grown on media and under conditions as recommended in the CCM
catalogue (see http://www.sci.muni.cz)
 Cultures may need at least one subculturing before they can be optimally used in experiments
 Unopened ampoules should be kept in a dark and cool place!
Figure 1: from CCM document ’Instructions for Opening 
and Reviving of Freeze-Dried Bacteria and Fungi’ available 
on http://www.sci.muni.cz 
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SUBCULTURE AND MAINTENANCE OF    
QUALITY CONTROL STRAINS 
1 PURPOSE AND REFERENCES  
Improper storage and repeated subculturing of bacteria can produce alterations in antimicrobial 
susceptibility test results. The Clinical and Laboratory Standards Institute (CLSI) has published 
guidelines for Quality Control (QC) stock culture maintenance to ensure consistent antimicrobial 
susceptibility test (AST) results.  
The following can be regarded as a summary of information that should be followed for 
subculturing and maintaining QC-strains when performing AST by broth dilution methods. For full 
information related to this subject, the following standards are relevant: M100 (Performance 
Standards for Antimicrobial Susceptibility Testing) and M7 (Methods for Dilution Antimicrobial 
Susceptibility Test for Bacteria That Grow Aerobically; Approved Standard). 
2 DEFINITION OF TERMS 
Reference Culture: A reference culture is a microorganism preparation that is acquired from a 
culture type collection.  
Reference Stock Culture: A reference stock culture is a microorganism preparation that is derived 
from a reference culture. Guidelines and standards outline how reference stock cultures must be 
processed and stored.  
Working Stock Cultures: A working stock culture is growth derived from a reference stock culture. 
Guidelines and standards outline how working stock cultures must be processed and how often they 
can be subcultured.  
Subcultures (Passages): A subculture is simply the transfer of established microorganism growth on 
media to fresh media. The subsequent growth on the fresh media constitutes a subculture or 
passage. Growing a reference culture or reference stock culture from its preserved status (frozen or 
lyophilized) is not a subculture. The preserved microorganism is not in a stage of established 
growth until it is thawed or hydrated and grown for the first time. 
3 IMPORTANT CONSIDERATIONS 
 Do not use disc diffusion strains for MIC determination. 
 Obtain QC strains from a reliable source such as ATCC. 
 CLSI requires that QC be performed either on the same day or weekly (after QC-validation). 
 Any changes in materials or procedure must be validated with QC before implemented 
 For example: Agar and broth methods may give different QC ranges for drugs such as 
glycopeptides, aminoglycosides and macrolides. 
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 Periodically perform colony counts to check the inoculum preparation procedure.
 Ideally, test values should be in the middle of the acceptable range.
 Graphing QC data points over time can help identify changes in data helpful for
troubleshooting problems.
4 STORAGE OF REFERENCE STRAINS 
Preparation of stock cultures 
 Use a suitable stabilizer such as 50% fetal calf serum in broth, 10-15% glycerol in tryptic
soy broth, defibrinated sheep blood or skim milk to prepare multiple aliquots.
 Store at -20°C, -70°C or liquid nitrogen (alternatively, freeze dry.)
 Before using rejuvenated strains for QC, subculture to check for purity and viability.
Working cultures 
 Set up on agar slants with appropriate medium, store at 4-8°C and subculture weekly.
 Replace the working strain with a stock culture at least monthly.
 If a change in the organisms inherent susceptibility occurs, obtain a fresh stock culture or a
new strain from a reference culture collection e.g. ATCC.
5 FREQUENCY OF TESTING 
Weekly vs. daily testing  
Weekly testing is possible if the laboratory can demonstrate satisfactory performance with daily 
testing according to the descriptions in the CLSI guidelines. 
 Documentation showing reference strain results from 20 or 30 consecutive test days were
within the acceptable range.
 For each antimicrobial/organism combination, no more one out of 20 or three out of 30 MIC
values may be outside the acceptable range.
When the above are fulfilled, each quality control strain may be tested once a week and whenever 
any reagent component is changed. 
Corrective Actions  
If an MIC is outside the range in weekly testing, corrective action is required as follows: 
 Repeat the test if there is an obvious error e.g. wrong strain or incubation conditions used
 If there is no obvious error, return to daily control testing
If five acceptable QC results are available, no additional days of QC-testing are needed. 
If the problem cannot be resolved, continue daily testing until the errors are identified. 
Repeat the 30 days validation before resuming weekly testing. 
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Quality Control ranges for ATCC reference strains
Antimicrobial Microbroth                (36-37°C/48h)
Microbroth 
(42°C/24h)
Agar dilution     
(36-37°C/48h)
Agar dilution     
(42°C/24h)
Ciprofloxacin, CIP 0.06-0.25 0.03-0.12 0.12-1 0.06-0.5
Erythromycin, ERY 0.5-2 0.25-2 1-8 1-4
Gentamicin, GEN 0.5-2 0.25-2 0.5-2 0.5-4
Nalidixic acid, NAL 4-16 4-16 None None
Tetracycline, TET 0.25-2 0.25-1 None None
Campylobacter jejuni ATCC 33560
MIC ranges (µg/mL)  are according to CLSI (VET01-S2) 
Tigecycline, TGC 0.03-0.25
Trimethoprim, TMP 0.5-2
MIC ranges (µg/mL) are according to CLSI M100 27th edition (range for ciprofloxacin and 
ertapenem extended to include 0.016).
Sulfamethoxazole, SMX 8-32
Temocillin, TRM none
Tetracycline, TET 0.5-2
Imipenem, IMI 0.06-0.25
Meropenem, MERO 0.008-0.06
Nalidixic acid, NAL 1-4
Colistin, COL 0.25-2
Ertapenem, ETP 0.004-0.016
Gentamicin, GEN 0.25-1
Ceftazidime + clavulanic acid, T/C none
Chloramphenicol, CHL 2-8
Ciprofloxacin, CIP 0.004-0.016
Cefotaxime + clavulanic acid, F/C none
Cefoxitin, FOX 2-8
Ceftazidime, TAZ 0.06-0.5
Azithromycin, AZI none
Cefepime, FEP 0.015-0.12
Cefotaxime, FOT 0.03-0.12
E. coli ATCC 25922
Antimicrobial MIC
Ampicillin, AMP 2-8
Appendix 6a, page 1 of 8
Test results from the reference strain E. coli ATCC 25922
Lab no. Panel Antimicrobial Operator Value Low limit High limit Mark Method Temperature Time
2 1 Ampicillin = 4 2 8 1 MIC 35±1 18-24
2 1 Ampicillin AMP = 4 2 8 1 MIC 35±1 18-24
2 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 35±1 18-24
2 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 35±1 18-24
2 1 Chloramphenicol CHL <= 8 2 8 1 MIC 35±1 18-24
2 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 35±1 18-24
2 1 Colistin COL <= 1   0.25 2 1 MIC 35±1 18-24
2 1 Gentamicin GEN <=   0.5   0.25 1 1 MIC 35±1 18-24
2 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 35±1 18-24
2 1 Nalidixic acid NAL <= 4 1 4 1 MIC 35±1 18-24
2 1 Sulfamethoxazole SMX = 32 8 32 1 MIC 35±1 18-24
2 1 Tetracycline TET <= 2   0.5 2 1 MIC 35±1 18-24
2 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 35±1 18-24
2 1 Trimethoprim TMP =   0.5   0.5 2 1 MIC 35±1 18-24
2 2 Cefepime FEP <=   0.06   0.016   0.12 1 MIC 35±1 18-24
2 2 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 35±1 18-24
2 2 Cefoxitin FOX = 4 2 8 1 MIC 35±1 18-24
2 2 Ceftazidime TAZ <=   0.25   0.06   0.5 1 MIC 35±1 18-24
2 2 Ertapenem ETP <=   0.015   0.004   0.016 1 MIC 35±1 18-24
2 2 Imipenem IMI =   0.25   0.06   0.25 1 MIC 35±1 18-24
2 2 Meropenem MER <=   0.03   0.008   0.06 1 MIC 35±1 18-24
4 1 Ampicillin AMP = 4 2 8 1 MIC 37°C 24
4 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 37°C 24
4 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 37°C 24
4 1 Chloramphenicol CHL <= 8 2 8 1 MIC 37°C 24
4 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 37°C 24
4 1 Colistin COL <= 1   0.25 2 1 MIC 37°C 24
4 1 Gentamicin GEN <=   0.5   0.25 1 1 MIC 37°C 24
4 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 37°C 24
4 1 Nalidixic acid NAL <= 4 1 4 1 MIC 37°C 24
4 1 Sulfamethoxazole SMX = 32 8 32 1 MIC 37°C 24
4 1 Tetracycline TET <= 2   0.5 2 1 MIC 37°C 24
4 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 37°C 24
4 1 Trimethoprim TMP = 1   0.5 2 1 MIC 37°C 24
6 1 Ampicillin AMP = 8 2 8 1 MIC 35 18
6 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 35 18
6 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 35 18
6 1 Chloramphenicol CHL <= 8 2 8 1 MIC 35 18
6 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 35 18
6 1 Colistin COL <= 1   0.25 2 1 MIC 35 18
6 1 Gentamicin GEN <=   0.5   0.25 1 1 MIC 35 18
6 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 35 18
6 1 Nalidixic acid NAL <= 4 1 4 1 MIC 35 18
6 1 Sulfamethoxazole SMX = 32 8 32 1 MIC 35 18
6 1 Tetracycline TET <= 2   0.5 2 1 MIC 35 18
6 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 35 18
6 1 Trimethoprim TMP = 1   0.5 2 1 MIC 35 18
6 2 Cefepime FEP <=   0.06   0.016   0.12 1 MIC 35 18
6 2 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 35 18
6 2 Cefoxitin FOX = 4 2 8 1 MIC 35 18
6 2 Ceftazidime TAZ <=   0.025   0.06   0.5 0 MIC 35 18
6 2 Ertapenem ETP <=   0.015   0.004   0.016 1 MIC 35 18
6 2 Imipenem IMI =   0.25   0.06   0.25 1 MIC 35 18
6 2 Meropenem MER <=   0.03   0.008   0.06 1 MIC 35 18
9 1 Ampicillin AMP = 4 2 8 1 MIC 35+-1 20
9 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 35+-1 20
9 1 Chloramphenicol CHL <= 8 2 8 1 MIC 35+-1 20
9 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 35+-1 20
9 1 Colistin COL <= 1   0.25 2 1 MIC 35+-1 20
9 1 Gentamicin GEN <=   0.5   0.25 1 1 MIC 35+-1 20
9 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 35+-1 20
9 1 Nalidixic acid NAL <= 4 1 4 1 MIC 35+-1 20
9 1 Sulfamethoxazole SMX = 16 8 32 1 MIC 35+-1 20
9 1 Tetracycline TET <= 2   0.5 2 1 MIC 35+-1 20
9 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 35+-1 20
9 1 Trimethoprim TMP = 1   0.5 2 1 MIC 35+-1 20
9 2 Cefepime FEP <=   0.06   0.016   0.12 1 MIC 35+-1 20
9 2 Cefoxitin FOX = 4 2 8 1 MIC 35+-1 20
9 2 Ceftazidime TAZ <=   0.25   0.06   0.5 1 MIC 35+-1 20
9 2 Ertapenem ETP <=   0.015   0.004   0.016 1 MIC 35+-1 20
9 2 Imipenem IMI <=   0.12   0.06   0.25 1 MIC 35+-1 20
9 2 Meropenem MER <=   0.03   0.008   0.06 1 MIC 35+-1 20
11 1 Ampicillin AMP = 2 2 8 1 MIC 35 18-20
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11 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 35 18-20
11 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 35 18-20
11 1 Chloramphenicol CHL <= 8 2 8 1 MIC 35 18-20
11 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 35 18-20
11 1 Colistin COL <= 1   0.25 2 1 MIC 35 18-20
11 1 Gentamicin GEN = 1   0.25 1 1 MIC 35 18-20
11 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 35 18-20
11 1 Nalidixic acid NAL <= 4 1 4 1 MIC 35 18-20
11 1 Sulfamethoxazole SMX = 16 8 32 1 MIC 35 18-20
11 1 Tetracycline TET <= 2   0.5 2 1 MIC 35 18-20
11 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 35 18-20
11 1 Trimethoprim TMP =   0.5   0.5 2 1 MIC 35 18-20
11 2 Cefepime FEP <=   0.06   0.016   0.12 1 MIC 35 18-20
11 2 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 35 18-20
11 2 Cefoxitin FOX = 2 2 8 1 MIC 35 18-20
11 2 Ceftazidime TAZ <=   0.05   0.06   0.5 0 MIC 35 18-20
11 2 Ertapenem ETP <=   0.015   0.004   0.016 1 MIC 35 18-20
11 2 Imipenem IMI <=   0.12   0.06   0.25 1 MIC 35 18-20
11 2 Meropenem MER <=   0.03   0.008   0.06 1 MIC 35 18-20
12 1 Ampicillin AMP = 4 2 8 1 MIC 35 18-30
12 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 35 18-30
12 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 35 18-30
12 1 Chloramphenicol CHL <= 8 2 8 1 MIC 35 18-30
12 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 35 18-30
12 1 Colistin COL <= 1   0.25 2 1 MIC 35 18-30
12 1 Gentamicin GEN <=   0.5   0.25 1 1 MIC 35 18-30
12 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 35 18-30
12 1 Nalidixic acid NAL <= 4 1 4 1 MIC 35 18-30
12 1 Sulfamethoxazole SMX <= 8 8 32 1 MIC 35 18-30
12 1 Tetracycline TET <= 2   0.5 2 1 MIC 35 18-30
12 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 35 18-30
12 1 Trimethoprim TMP = 1   0.5 2 1 MIC 35 18-30
12 2 Cefepime FEP <=   0.06   0.016   0.12 1 MIC 35 18-30
12 2 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 35 18-30
12 2 Cefoxitin FOX = 4 2 8 1 MIC 35 18-30
12 2 Ceftazidime TAZ <=   0.25   0.06   0.5 1 MIC 35 18-30
12 2 Ertapenem ETP <=   0.015   0.004   0.016 1 MIC 35 18-30
12 2 Imipenem IMI <=   0.12   0.06   0.25 1 MIC 35 18-30
12 2 Meropenem MER <=   0.03   0.008   0.06 1 MIC 35 18-30
16 1 Ampicillin AMP = 4 2 8 1 MIC 35 18-24
16 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 35 18-24
16 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 35 18-24
16 1 Chloramphenicol CHL <= 8 2 8 1 MIC 35 18-24
16 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 35 18-24
16 1 Colistin COL <= 1   0.25 2 1 MIC 35 18-24
16 1 Gentamicin GEN <=   0.5   0.25 1 1 MIC 35 18-24
16 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 35 18-24
16 1 Nalidixic acid NAL <= 4 1 4 1 MIC 35 18-24
16 1 Sulfamethoxazole SMX = 32 8 32 1 MIC 35 18-24
16 1 Tetracycline TET <= 2   0.5 2 1 MIC 35 18-24
16 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 35 18-24
16 1 Trimethoprim TMP =   0.5   0.5 2 1 MIC 35 18-24
16 2 Cefepime FEP <=   0.06   0.016   0.12 1 MIC 35 18-24
16 2 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 35 18-24
16 2 Cefoxitin FOX = 4 2 8 1 MIC 35 18-24
16 2 Ceftazidime TAZ <=   0.25   0.06   0.5 1 MIC 35 18-24
16 2 Ertapenem ETP <=   0.015   0.004   0.016 1 MIC 35 18-24
16 2 Imipenem IMI =   0.25   0.06   0.25 1 MIC 35 18-24
16 2 Meropenem MER <=   0.03   0.008   0.06 1 MIC 35 18-24
17 1 Ampicillin AMP = 8 2 8 1 MIC 37 18
17 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 37 18
17 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 37 18
17 1 Chloramphenicol CHL <= 8 2 8 1 MIC 37 18
17 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 37 18
17 1 Colistin COL <= 1   0.25 2 1 MIC 37 18
17 1 Gentamicin GEN <=   0.5   0.25 1 1 MIC 37 18
17 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 37 18
17 1 Nalidixic acid NAL <= 4 1 4 1 MIC 37 18
17 1 Sulfamethoxazole SMX <= 8 8 32 1 MIC 37 18
17 1 Tetracycline TET <= 2   0.5 2 1 MIC 37 18
17 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 37 18
17 1 Trimethoprim TMP <=   0.25   0.5 2 0 MIC 37 18
17 2 Cefepime FEP <=   0.06   0.016   0.12 1 MIC 37 18
17 2 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 37 18
17 2 Cefoxitin FOX = 8 2 8 1 MIC 37 18
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17 2 Ceftazidime TAZ =   0.5   0.06   0.5 1 MIC 37 18
17 2 Ertapenem ETP <=   0.015   0.004   0.016 1 MIC 37 18
17 2 Imipenem IMI =   0.25   0.06   0.25 1 MIC 37 18
17 2 Meropenem MER <=   0.03   0.008   0.06 1 MIC 37 18
18 1 Ampicillin AMP = 2 2 8 1 MIC 37 18
18 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 37 18
18 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 37 18
18 1 Chloramphenicol CHL <= 8 2 8 1 MIC 37 18
18 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 37 18
18 1 Colistin COL <= 1   0.25 2 1 MIC 37 18
18 1 Gentamicin GEN <=   0.5   0.25 1 1 MIC 37 18
18 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 37 18
18 1 Nalidixic acid NAL <= 4 1 4 1 MIC 37 18
18 1 Sulfamethoxazole SMX = 16 8 32 1 MIC 37 18
18 1 Tetracycline TET <= 2   0.5 2 1 MIC 37 18
18 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 37 18
18 1 Trimethoprim TMP =   0.5   0.5 2 1 MIC 37 18
18 2 Cefepime FEP <=   0.06   0.016   0.12 1 MIC 37 18
18 2 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 37 18
18 2 Cefoxitin FOX = 2 2 8 1 MIC 37 18
18 2 Ceftazidime TAZ <=   0.25   0.06   0.5 1 MIC 37 18
18 2 Ertapenem ETP <=   0.015   0.004   0.016 1 MIC 37 18
18 2 Imipenem IMI <=   0.12   0.06   0.25 1 MIC 37 18
18 2 Meropenem MER <=   0.03   0.008   0.06 1 MIC 37 18
19 1 Ampicillin AMP = 4 2 8 1 MIC 35 18
19 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 35 18
19 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 35 18
19 1 Chloramphenicol CHL <= 8 2 8 1 MIC 35 18
19 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 35 18
19 1 Colistin COL <= 1   0.25 2 1 MIC 35 18
19 1 Gentamicin GEN <=   0.5   0.25 1 1 MIC 35 18
19 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 35 18
19 1 Nalidixic acid NAL <= 4 1 4 1 MIC 35 18
19 1 Sulfamethoxazole SMX = 32 8 32 1 MIC 35 18
19 1 Tetracycline TET <= 2   0.5 2 1 MIC 35 18
19 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 35 18
19 1 Trimethoprim TMP =   0.5   0.5 2 1 MIC 35 18
19 2 Cefepime FEP <=   0.06   0.016   0.12 1 MIC 35 18
19 2 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 35 18
19 2 Cefoxitin FOX = 2 2 8 1 MIC 35 18
19 2 Ceftazidime TAZ <=   0.25   0.06   0.5 1 MIC 35 18
19 2 Ertapenem ETP <=   0.015   0.004   0.016 1 MIC 35 18
19 2 Imipenem IMI <=   0.12   0.06   0.25 1 MIC 35 18
19 2 Meropenem MER <=   0.03   0.008   0.06 1 MIC 35 18
20 1 Ampicillin AMP = 4 2 8 1 MIC 37C +/- 1C 20h +/- 2h
20 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 37C +/- 1C 20h +/- 2h
20 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 37C +/- 1C 20h +/- 2h
20 1 Chloramphenicol CHL <= 8 2 8 1 MIC 37C +/- 1C 20h +/- 2h
20 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 37C +/- 1C 20h +/- 2h
20 1 Colistin COL <= 1   0.25 2 1 MIC 37C +/- 1C 20h +/- 2h
20 1 Gentamicin GEN <=   0.5   0.25 1 1 MIC 37C +/- 1C 20h +/- 2h
20 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 37C +/- 1C 20h +/- 2h
20 1 Nalidixic acid NAL <= 4 1 4 1 MIC 37C +/- 1C 20h +/- 2h
20 1 Sulfamethoxazole SMX = 16 8 32 1 MIC 37C +/- 1C 20h +/- 2h
20 1 Tetracycline TET <= 2   0.5 2 1 MIC 37C +/- 1C 20h +/- 2h
20 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 37C +/- 1C 20h +/- 2h
20 1 Trimethoprim TMP =   0.5   0.5 2 1 MIC 37C +/- 1C 20h +/- 2h
20 2 Cefepime FEP <=   0.06   0.016   0.12 1 MIC 37C +/- 1C 20h +/- 2h
20 2 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 37C +/- 1C 20h +/- 2h
20 2 Cefoxitin FOX = 2 2 8 1 MIC 37C +/- 1C 20h +/- 2h
20 2 Ceftazidime TAZ <=   0.25   0.06   0.5 1 MIC 37C +/- 1C 20h +/- 2h
20 2 Ertapenem ETP <=   0.015   0.004   0.016 1 MIC 37C +/- 1C 20h +/- 2h
20 2 Imipenem IMI <=   0.12   0.06   0.25 1 MIC 37C +/- 1C 20h +/- 2h
20 2 Meropenem MER <=   0.03   0.008   0.06 1 MIC 37C +/- 1C 20h +/- 2h
21 1 Ampicillin AMP = 4 2 8 1 MIC 36 24
21 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 36 24
21 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 36 24
21 1 Chloramphenicol CHL <= 8 2 8 1 MIC 36 24
21 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 36 24
21 1 Colistin COL <= 1   0.25 2 1 MIC 36 24
21 1 Gentamicin GEN <=   0.5   0.25 1 1 MIC 36 24
21 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 36 24
21 1 Nalidixic acid NAL <= 4 1 4 1 MIC 36 24
21 1 Sulfamethoxazole SMX = 16 8 32 1 MIC 36 24
21 1 Tetracycline TET <= 2   0.5 2 1 MIC 36 24
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21 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 36 24
21 1 Trimethoprim TMP =   0.5   0.5 2 1 MIC 36 24
21 2 Cefepime FEP <=   0.06   0.016   0.12 1 MIC 36 24
21 2 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 36 24
21 2 Cefoxitin FOX = 4 2 8 1 MIC 36 24
21 2 Ceftazidime TAZ <=   0.25   0.06   0.5 1 MIC 36 24
21 2 Ertapenem ETP <=   0.015   0.004   0.016 1 MIC 36 24
21 2 Imipenem IMI <=   0.12   0.06   0.25 1 MIC 36 24
21 2 Meropenem MER <=   0.03   0.008   0.06 1 MIC 36 24
22 1 Ampicillin AMP = 4 2 8 1 MIC 36 20
22 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 36 20
22 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 36 20
22 1 Chloramphenicol CHL <= 8 2 8 1 MIC 36 20
22 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 36 20
22 1 Colistin COL <= 1   0.25 2 1 MIC 36 20
22 1 Gentamicin GEN = 1   0.25 1 1 MIC 36 20
22 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 36 20
22 1 Nalidixic acid NAL <= 4 1 4 1 MIC 36 20
22 1 Sulfamethoxazole SMX = 32 8 32 1 MIC 36 20
22 1 Tetracycline TET <= 2   0.5 2 1 MIC 36 20
22 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 36 20
22 1 Trimethoprim TMP =   0.5   0.5 2 1 MIC 36 20
22 2 Cefepime FEP <=   0.06   0.016   0.12 1 MIC 36 20
22 2 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 36 20
22 2 Cefoxitin FOX = 2 2 8 1 MIC 36 20
22 2 Ceftazidime TAZ <=   0.25   0.06   0.5 1 MIC 36 20
22 2 Ertapenem ETP <=   0.015   0.004   0.016 1 MIC 36 20
22 2 Imipenem IMI <=   0.12   0.06   0.25 1 MIC 36 20
22 2 Meropenem MER <=   0.03   0.008   0.06 1 MIC 36 20
23 1 Ampicillin AMP = 4 2 8 1 MIC
23 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC
23 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC
23 1 Chloramphenicol CHL <= 8 2 8 1 MIC
23 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC
23 1 Colistin COL <= 1   0.25 2 1 MIC
23 1 Gentamicin GEN <=   0.5   0.25 1 1 MIC
23 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC
23 1 Nalidixic acid NAL <= 4 1 4 1 MIC
23 1 Sulfamethoxazole SMX = 16 8 32 1 MIC
23 1 Tetracycline TET <= 2   0.5 2 1 MIC
23 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC
23 1 Trimethoprim TMP =   0.5   0.5 2 1 MIC
23 2 Cefepime FEP =   0.06   0.016   0.12 1 MIC
23 2 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC
23 2 Cefoxitin FOX = 2 2 8 1 MIC
23 2 Ceftazidime TAZ =   0.25   0.06   0.5 1 MIC
23 2 Ertapenem ETP =   0.015   0.004   0.016 1 MIC
23 2 Imipenem IMI =   0.25   0.06   0.25 1 MIC
23 2 Meropenem MER =   0.03   0.008   0.06 1 MIC
25 1 Ampicillin AMP = 4 2 8 1 MIC 35 16 - 20
25 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 35 16 - 20
25 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 35 16 - 20
25 1 Chloramphenicol CHL <= 8 2 8 1 MIC 35 16 - 20
25 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 35 16 - 20
25 1 Colistin COL <= 1   0.25 2 1 MIC 35 16 - 20
25 1 Gentamicin GEN = 2   0.25 1 0 MIC 35 16 - 20
25 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 35 16 - 20
25 1 Nalidixic acid NAL <= 4 1 4 1 MIC 35 16 - 20
25 1 Sulfamethoxazole SMX <= 8 8 32 1 MIC 35 16 - 20
25 1 Tetracycline TET <= 2   0.5 2 1 MIC 35 16 - 20
25 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 35 16 - 20
25 1 Trimethoprim TMP =   0.5   0.5 2 1 MIC 35 16 - 20
25 2 Cefepime FEP <=   0.06   0.016   0.12 1 MIC 35 16 - 20
25 2 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 35 16 - 20
25 2 Cefoxitin FOX = 2 2 8 1 MIC 35 16 - 20
25 2 Ceftazidime TAZ <=   0.25   0.06   0.5 1 MIC 35 16 - 20
25 2 Ertapenem ETP <=   0.015   0.004   0.016 1 MIC 35 16 - 20
25 2 Imipenem IMI =   0.25   0.06   0.25 1 MIC 35 16 - 20
25 2 Meropenem MER <=   0.03   0.008   0.06 1 MIC 35 16 - 20
26 1 Ampicillin AMP = 2 2 8 1 MIC 37 18
26 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 37 18
26 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 37 18
26 1 Chloramphenicol CHL <= 8 2 8 1 MIC 37 18
26 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 37 18
26 1 Colistin COL <= 1   0.25 2 1 MIC 37 18
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26 1 Gentamicin GEN = 1   0.25 1 1 MIC 37 18
26 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 37 18
26 1 Nalidixic acid NAL <= 4 1 4 1 MIC 37 18
26 1 Sulfamethoxazole SMX = 64 8 32 0 MIC 37 18
26 1 Tetracycline TET <= 2   0.5 2 1 MIC 37 18
26 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 37 18
26 1 Trimethoprim TMP =   0.5   0.5 2 1 MIC 37 18
29 1 Ampicillin AMP = 4 2 8 1 MIC 37 18
29 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 37 18
29 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 37 18
29 1 Chloramphenicol CHL <= 8 2 8 1 MIC 37 18
29 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 37 18
29 1 Colistin COL <= 1   0.25 2 1 MIC 37 18
29 1 Gentamicin GEN <=   0.5   0.25 1 1 MIC 37 18
29 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 37 18
29 1 Nalidixic acid NAL <= 4 1 4 1 MIC 37 18
29 1 Sulfamethoxazole SMX = 16 8 32 1 MIC 37 18
29 1 Tetracycline TET <= 2   0.5 2 1 MIC 37 18
29 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 37 18
29 1 Trimethoprim TMP = 1   0.5 2 1 MIC 37 18
29 2 Cefepime FEP <=   0.06   0.016   0.12 1 MIC 37 18
29 2 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 37 18
29 2 Cefoxitin FOX = 2 2 8 1 MIC 37 18
29 2 Ceftazidime TAZ <=   0.25   0.06   0.5 1 MIC 37 18
29 2 Ertapenem ETP <=   0.015   0.004   0.016 1 MIC 37 18
29 2 Imipenem IMI <=   0.12   0.06   0.25 1 MIC 37 18
29 2 Meropenem MER <=   0.03   0.008   0.06 1 MIC 37 18
30 1 Ampicillin AMP = 4 2 8 1 MIC
30 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC
30 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC
30 1 Chloramphenicol CHL <= 8 2 8 1 MIC
30 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC
30 1 Colistin COL <= 1   0.25 2 1 MIC
30 1 Gentamicin GEN <=   0.5   0.25 1 1 MIC
30 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC
30 1 Nalidixic acid NAL <= 4 1 4 1 MIC
30 1 Sulfamethoxazole SMX = 16 8 32 1 MIC
30 1 Tetracycline TET <= 2   0.5 2 1 MIC
30 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC
30 1 Trimethoprim TMP =   0.5   0.5 2 1 MIC
30 2 Cefepime FEP <=   0.06   0.016   0.12 1 MIC
30 2 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC
30 2 Cefoxitin FOX = 2 2 8 1 MIC
30 2 Ceftazidime TAZ <=   0.25   0.06   0.5 1 MIC
30 2 Ertapenem ETP <=   0.015   0.004   0.016 1 MIC
30 2 Imipenem IMI <=   0.12   0.06   0.25 1 MIC
30 2 Meropenem MER <=   0.03   0.008   0.06 1 MIC
32 1 Ampicillin AMP = 8 2 8 1 MIC 37º +/- 1 18+/-2h
32 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 37º +/- 1 18+/-2h
32 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 37º +/- 1 18+/-2h
32 1 Chloramphenicol CHL <= 8 2 8 1 MIC 37º +/- 1 18+/-2h
32 1 Ciprofloxacin CIP <=   0.15   0.004   0.016 1 MIC 37º +/- 1 18+/-2h
32 1 Colistin COL <= 1   0.25 2 1 MIC 37º +/- 1 18+/-2h
32 1 Gentamicin GEN <=   0.5   0.25 1 1 MIC 37º +/- 1 18+/-2h
32 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 37º +/- 1 18+/-2h
32 1 Nalidixic acid NAL <= 4 1 4 1 MIC 37º +/- 1 18+/-2h
32 1 Sulfamethoxazole SMX = 16 8 32 1 MIC 37º +/- 1 18+/-2h
32 1 Tetracycline TET <= 2   0.5 2 1 MIC 37º +/- 1 18+/-2h
32 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 37º +/- 1 18+/-2h
32 1 Trimethoprim TMP =   0.5   0.5 2 1 MIC 37º +/- 1 18+/-2h
32 2 Cefepime FEP <=   0.06   0.016   0.12 1 MIC 37º +/- 1 18+/-2h
32 2 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 37º +/- 1 18+/-2h
32 2 Cefoxitin FOX = 8 2 8 1 MIC 37º +/- 1 18+/-2h
32 2 Ceftazidime TAZ <=   0.25   0.06   0.5 1 MIC 37º +/- 1 18+/-2h
32 2 Ertapenem ETP <=   0.015   0.004   0.016 1 MIC 37º +/- 1 18+/-2h
32 2 Imipenem IMI <=   0.12   0.06   0.25 1 MIC 37º +/- 1 18+/-2h
32 2 Meropenem MER <=   0.03   0.008   0.06 1 MIC 37º +/- 1 18+/-2h
33 1 Ampicillin AMP = 4 2 8 1 MIC 35 16-18
33 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 35 16-18
33 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 35 16-18
33 1 Chloramphenicol CHL <= 8 2 8 1 MIC 35 16-18
33 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 35 16-18
33 1 Colistin COL <= 1   0.25 2 1 MIC 35 16-18
33 1 Gentamicin GEN <=   0.5   0.25 1 1 MIC 35 16-18
33 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 35 16-18
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33 1 Nalidixic acid NAL <= 4 1 4 1 MIC 35 16-18
33 1 Sulfamethoxazole SMX = 32 8 32 1 MIC 35 16-18
33 1 Tetracycline TET <= 2   0.5 2 1 MIC 35 16-18
33 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 35 16-18
33 1 Trimethoprim TMP = 1   0.5 2 1 MIC 35 16-18
33 2 Cefepime FEP =   0.12   0.016   0.12 1 MIC 35 16-18
33 2 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 35 16-18
33 2 Cefoxitin FOX = 4 2 8 1 MIC 35 16-18
33 2 Ceftazidime TAZ <=   0.25   0.06   0.5 1 MIC 35 16-18
33 2 Ertapenem ETP <=   0.015   0.004   0.016 1 MIC 35 16-18
33 2 Imipenem IMI <=   0.012   0.06   0.25 0 MIC 35 16-18
33 2 Meropenem MER <=   0.03   0.008   0.06 1 MIC 35 16-18
34 1 Ampicillin AMP = 4 2 8 1 MIC 37 24
34 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 37 24
34 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 37 24
34 1 Chloramphenicol CHL <= 8 2 8 1 MIC 37 24
34 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 37 24
34 1 Colistin COL <= 1   0.25 2 1 MIC 37 24
34 1 Gentamicin GEN <=   0.5   0.25 1 1 MIC 37 24
34 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 37 24
34 1 Nalidixic acid NAL <= 4 1 4 1 MIC 37 24
34 1 Sulfamethoxazole SMX = 16 8 32 1 MIC 37 24
34 1 Tetracycline TET <= 2   0.5 2 1 MIC 37 24
34 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 37 24
34 1 Trimethoprim TMP =   0.5   0.5 2 1 MIC 37 24
34 2 Cefepime FEP <=   0.06   0.016   0.12 1 MIC 37 24
34 2 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 37 24
34 2 Cefoxitin FOX = 4 2 8 1 MIC 37 24
34 2 Ceftazidime TAZ <=   0.25   0.06   0.5 1 MIC 37 24
34 2 Ertapenem ETP <=   0.015   0.004   0.016 1 MIC 37 24
34 2 Imipenem IMI <=   0.012   0.06   0.25 0 MIC 37 24
34 2 Meropenem MER <=   0.03   0.008   0.06 1 MIC 37 24
36 1 Ampicillin AMP = 8 2 8 1 MIC 35 18-24
36 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 35 18-24
36 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 35 18-24
36 1 Chloramphenicol CHL <= 8 2 8 1 MIC 35 18-24
36 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 35 18-24
36 1 Colistin COL <= 1   0.25 2 1 MIC 35 18-24
36 1 Gentamicin GEN <=   0.5   0.25 1 1 MIC 35 18-24
36 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 35 18-24
36 1 Nalidixic acid NAL <= 4 1 4 1 MIC 35 18-24
36 1 Sulfamethoxazole SMX <= 8 8 32 1 MIC 35 18-24
36 1 Tetracycline TET <= 2   0.5 2 1 MIC 35 18-24
36 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 35 18-24
36 1 Trimethoprim TMP = 1   0.5 2 1 MIC 35 18-24
36 2 Cefepime FEP <=   0.06   0.016   0.12 1 MIC 35 18-24
36 2 Cefotaxime FOT <=   0.06   0.03   0.12 1 MIC 35 18-24
36 2 Cefoxitin FOX = 4 2 8 1 MIC 35 18-24
36 2 Ceftazidime TAZ =   0.25   0.06   0.5 1 MIC 35 18-24
36 2 Ertapenem ETP <=   0.015   0.004   0.016 1 MIC 35 18-24
36 2 Imipenem IMI <=   0.12   0.06   0.25 1 MIC 35 18-24
36 2 Meropenem MER <=   0.03   0.008   0.06 1 MIC 35 18-24
37 1 Ampicillin AMP = 4 2 8 1 MIC 37ºC 18-24hours
37 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 37ºC 18-24hours
37 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 37ºC 18-24hours
37 1 Chloramphenicol CHL <= 8 2 8 1 MIC 37ºC 18-24hours
37 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 37ºC 18-24hours
37 1 Colistin COL <= 1   0.25 2 1 MIC 37ºC 18-24hours
37 1 Gentamicin GEN = 1   0.25 1 1 MIC 37ºC 18-24hours
37 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 37ºC 18-24hours
37 1 Nalidixic acid NAL <= 4 1 4 1 MIC 37ºC 18-24hours
37 1 Sulfamethoxazole SMX = 32 8 32 1 MIC 37ºC 18-24hours
37 1 Tetracycline TET <= 2   0.5 2 1 MIC 37ºC 18-24hours
37 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 37ºC 18-24hours
37 1 Trimethoprim TMP =   0.5   0.5 2 1 MIC 37ºC 18-24hours
39 1 Ampicillin AMP = 4 2 8 1 MIC
39 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC
39 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC
39 1 Chloramphenicol CHL <= 8 2 8 1 MIC
39 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC
39 1 Colistin COL <= 1   0.25 2 1 MIC
39 1 Gentamicin GEN <=   0.5   0.25 1 1 MIC
39 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC
39 1 Nalidixic acid NAL <= 4 1 4 1 MIC
39 1 Sulfamethoxazole SMX = 32 8 32 1 MIC
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39 1 Tetracycline TET <= 2   0.5 2 1 MIC
39 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC
39 1 Trimethoprim TMP =   0.5   0.5 2 1 MIC
39 2 Cefepime FEP <=   0.06   0.016   0.12 1 MIC
39 2 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC
39 2 Cefoxitin FOX = 4 2 8 1 MIC
39 2 Ceftazidime TAZ <=   0.25   0.06   0.5 1 MIC
39 2 Ertapenem ETP <=   0.015   0.004   0.016 1 MIC
39 2 Imipenem IMI <=   0.12   0.06   0.25 1 MIC
39 2 Meropenem MER <=   0.03   0.008   0.06 1 MIC
40 1 Ampicillin AMP = 2 2 8 1 MIC 37 20
40 1 Cefotaxime FOT =   0.12   0.03   0.12 1 MIC 37 20
40 1 Ceftazidime TAZ =   0.5   0.06   0.5 1 MIC 37 20
40 1 Chloramphenicol CHL = 8 2 8 1 MIC 37 20
40 1 Ciprofloxacin CIP =   0.015   0.004   0.016 1 MIC 37 20
40 1 Colistin COL = 1   0.25 2 1 MIC 37 20
40 1 Gentamicin GEN =   0.5   0.25 1 1 MIC 37 20
40 1 Meropenem MER =   0.03   0.008   0.06 1 MIC 37 20
40 1 Nalidixic acid NAL = 4 1 4 1 MIC 37 20
40 1 Sulfamethoxazole SMX = 16 8 32 1 MIC 37 20
40 1 Tetracycline TET = 2   0.5 2 1 MIC 37 20
40 1 Tigecycline TGC =   0.25   0.03   0.25 1 MIC 37 20
40 1 Trimethoprim TMP =   0.5   0.5 2 1 MIC 37 20
40 2 Cefepime FEP =   0.06   0.016   0.12 1 MIC 37 20
40 2 Cefotaxime FOT =   0.12   0.03   0.12 1 MIC 37 20
40 2 Cefoxitin FOX = 4 2 8 1 MIC 37 20
40 2 Ceftazidime TAZ =   0.5   0.06   0.5 1 MIC 37 20
40 2 Ertapenem ETP =   0.015   0.004   0.016 1 MIC 37 20
40 2 Imipenem IMI =   0.12   0.06   0.25 1 MIC 37 20
40 2 Meropenem MER =   0.03   0.008   0.06 1 MIC 37 20
42 1 Ampicillin AMP = 4 2 8 1 MIC 37°C 24 h
42 1 Cefotaxime FOT =   0.25   0.03   0.12 0 MIC 37°C 24 h
42 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 37°C 24 h
42 1 Chloramphenicol CHL <= 8 2 8 1 MIC 37°C 24 h
42 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 37°C 24 h
42 1 Colistin COL <= 1   0.25 2 1 MIC 37°C 24 h
42 1 Gentamicin GEN <=   0.5   0.25 1 1 MIC 37°C 24 h
42 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 37°C 24 h
42 1 Nalidixic acid NAL <= 4 1 4 1 MIC 37°C 24 h
42 1 Sulfamethoxazole SMX = 8 8 32 1 MIC 37°C 24 h
42 1 Tetracycline TET <= 2   0.5 2 1 MIC 37°C 24 h
42 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 37°C 24 h
42 1 Trimethoprim TMP =   0.5   0.5 2 1 MIC 37°C 24 h
42 2 Cefepime FEP =   0.06   0.016   0.12 1 MIC 37°C 24 h
42 2 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 37°C 24 h
42 2 Cefoxitin FOX = 4 2 8 1 MIC 37°C 24 h
42 2 Ceftazidime TAZ <=   0.25   0.06   0.5 1 MIC 37°C 24 h
42 2 Ertapenem ETP <=   0.015   0.004   0.016 1 MIC 37°C 24 h
42 2 Imipenem IMI <=   0.12   0.06   0.25 1 MIC 37°C 24 h
42 2 Meropenem MER <=   0.03   0.008   0.06 1 MIC 37°C 24 h
45 1 Ampicillin AMP = 8 2 8 1 MIC 36 18-22
45 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 36 18-22
45 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 36 18-22
45 1 Chloramphenicol CHL <= 8 2 8 1 MIC 36 18-22
45 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 36 18-22
45 1 Colistin COL <= 1   0.25 2 1 MIC 36 18-22
45 1 Gentamicin GEN <=   0.5   0.25 1 1 MIC 36 18-22
45 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 36 18-22
45 1 Nalidixic acid NAL <= 4 1 4 1 MIC 36 18-22
45 1 Sulfamethoxazole SMX = 16 8 32 1 MIC 36 18-22
45 1 Tetracycline TET <= 2   0.5 2 1 MIC 36 18-22
45 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 36 18-22
45 1 Trimethoprim TMP =   0.5   0.5 2 1 MIC 36 18-22
45 2 Cefepime FEP <=   0.06   0.016   0.12 1 MIC 36 18-22
45 2 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 36 18-22
45 2 Cefoxitin FOX = 4 2 8 1 MIC 36 18-22
45 2 Ceftazidime TAZ <=   0.25   0.06   0.5 1 MIC 36 18-22
45 2 Ertapenem ETP <=   0.015   0.004   0.016 1 MIC 36 18-22
45 2 Imipenem IMI <=   0.12   0.06   0.25 1 MIC 36 18-22
45 2 Meropenem MER <=   0.03   0.008   0.06 1 MIC 36 18-22
56 1 Ampicillin AMP = 4 2 8 1 MIC 35 20
56 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 35 20
56 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 35 20
56 1 Chloramphenicol CHL <= 8 2 8 1 MIC 35 20
56 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 35 20
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56 1 Colistin COL <= 1   0.25 2 1 MIC 35 20
56 1 Gentamicin GEN <=   0.5   0.25 1 1 MIC 35 20
56 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 35 20
56 1 Nalidixic acid NAL <= 4 1 4 1 MIC 35 20
56 1 Sulfamethoxazole SMX = 16 8 32 1 MIC 35 20
56 1 Tetracycline TET <= 2   0.5 2 1 MIC 35 20
56 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 35 20
56 1 Trimethoprim TMP =   0.5   0.5 2 1 MIC 35 20
56 2 Cefepime FEP <=   0.06   0.016   0.12 1 MIC 35 20
56 2 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 35 20
56 2 Cefoxitin FOX = 2 2 8 1 MIC 35 20
56 2 Ceftazidime TAZ <=   0.25   0.06   0.5 1 MIC 35 20
56 2 Ertapenem ETP <=   0.015   0.004   0.016 1 MIC 35 20
56 2 Imipenem IMI <=   0.12   0.06   0.25 1 MIC 35 20
56 2 Meropenem MER <=   0.03   0.008   0.06 1 MIC 35 20
58 1 Ampicillin AMP = 8 2 8 1 MIC 37 20
58 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 37 20
58 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 37 20
58 1 Chloramphenicol CHL <= 8 2 8 1 MIC 37 20
58 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 37 20
58 1 Colistin COL <= 1   0.25 2 1 MIC 37 20
58 1 Gentamicin GEN <=   0.5   0.25 1 1 MIC 37 20
58 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 37 20
58 1 Nalidixic acid NAL <= 4 1 4 1 MIC 37 20
58 1 Sulfamethoxazole SMX = 32 8 32 1 MIC 37 20
58 1 Tetracycline TET <= 2   0.5 2 1 MIC 37 20
58 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 37 20
58 1 Trimethoprim TMP = 1   0.5 2 1 MIC 37 20
58 2 Cefepime FEP <=   0.06   0.016   0.12 1 MIC 37 20
58 2 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 37 20
58 2 Cefoxitin FOX = 4 2 8 1 MIC 37 20
58 2 Ceftazidime TAZ <=   0.25   0.06   0.5 1 MIC 37 20
58 2 Ertapenem ETP <=   0.015   0.004   0.016 1 MIC 37 20
58 2 Imipenem IMI <=   0.12   0.06   0.25 1 MIC 37 20
58 2 Meropenem MER <=   0.03   0.008   0.06 1 MIC 37 20
59 1 Ampicillin AMP = 4 2 8 1 MIC 35 18-24
59 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 35 18-24
59 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 35 18-24
59 1 Chloramphenicol CHL <= 8 2 8 1 MIC 35 18-24
59 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 35 18-24
59 1 Colistin COL <= 1   0.25 2 1 MIC 35 18-24
59 1 Gentamicin GEN <=   0.5   0.25 1 1 MIC 35 18-24
59 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 35 18-24
59 1 Nalidixic acid NAL <= 4 1 4 1 MIC 35 18-24
59 1 Tetracycline TET <= 2   0.5 2 1 MIC 35 18-24
59 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 35 18-24
59 1 Trimethoprim TMP =   0.5   0.5 2 1 MIC 35 18-24
59 2 Cefepime FEP <=   0.06   0.016   0.12 1 MIC 35 18-24
59 2 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 35 18-24
59 2 Cefoxitin FOX = 2 2 8 1 MIC 35 18-24
59 2 Ceftazidime TAZ =   0.25   0.06   0.5 1 MIC 35 18-24
59 2 Ertapenem ETP <=   0.015   0.004   0.016 1 MIC 35 18-24
59 2 Imipenem IMI =   0.25   0.06   0.25 1 MIC 35 18-24
59 2 Meropenem MER <=   0.03   0.008   0.06 1 MIC 35 18-24
60 1 Ampicillin AMP = 4 2 8 1 MIC 35-37 18-20
60 1 Cefotaxime FOT <=   0.25   0.03   0.12 1 MIC 35-37 18-20
60 1 Ceftazidime TAZ <=   0.5   0.06   0.5 1 MIC 35-37 18-20
60 1 Chloramphenicol CHL <= 8 2 8 1 MIC 35-37 18-20
60 1 Ciprofloxacin CIP <=   0.015   0.004   0.016 1 MIC 35-37 18-20
60 1 Colistin COL <= 1   0.25 2 1 MIC 35-37 18-20
60 1 Gentamicin GEN <=   0.5   0.25 1 1 MIC 35-37 18-20
60 1 Meropenem MER <=   0.03   0.008   0.06 1 MIC 35-37 18-20
60 1 Nalidixic acid NAL <= 4 1 4 1 MIC 35-37 18-20
60 1 Sulfamethoxazole SMX <= 8 8 32 1 MIC 35-37 18-20
60 1 Tetracycline TET <= 2   0.5 2 1 MIC 35-37 18-20
60 1 Tigecycline TGC <=   0.25   0.03   0.25 1 MIC 35-37 18-20
60 1 Trimethoprim TMP <=   0.25   0.5 2 0 MIC 35-37 18-20
MIC: Microbroth dilution
AGA: Agar dilution
Appendix 6b, page 1 of 2
Test results from the reference strain C. jejuni ATCC 33560
Lab no. Antimicrobial Operator Value Low limit High limit Mark Method 36-37ºC/48h 42ºC/24h
2 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
2 Erythromycin = 1 0.5 2 1 MIC X
2 Gentamicin = 0.5 0.5 2 1 MIC X
2 Nalidixic acid = 8 4 16 1 MIC X
2 Tetracycline = 2 0.25 2 1 MIC X
6 Ciprofloxacin <= 0.12 0.03 0.125 1 MIC X
6 Erythromycin <= 1 0.25 2 1 MIC X
6 Gentamicin = 1 0.25 2 1 MIC X
6 Nalidixic acid = 8 4 16 1 MIC X
6 Tetracycline = 1 0.25 1 1 MIC X
9 Ciprofloxacin <= 0.12 0.06 0.25 1 MIC X
9 Erythromycin <= 1 0.5 2 1 MIC X
9 Gentamicin = 1 0.5 2 1 MIC X
9 Nalidixic acid = 8 4 16 1 MIC X
9 Tetracycline = 1 0.25 2 1 MIC X
11 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
11 Erythromycin = 2 0.5 2 1 MIC X
11 Gentamicin = 2 0.5 2 1 MIC X
11 Nalidixic acid = 8 4 16 1 MIC X
11 Tetracycline = 1 0.25 2 1 MIC X
12 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
12 Erythromycin <= 1 0.5 2 1 MIC X
12 Gentamicin = 1 0.5 2 1 MIC X
12 Nalidixic acid = 8 4 16 1 MIC X
12 Tetracycline = 1 0.25 2 1 MIC X
14 Ciprofloxacin <= 0.125 0.03 0.125 1 MIC X
14 Erythromycin <= 1 0.25 2 1 MIC X
14 Gentamicin = 0.5 0.25 2 1 MIC X
14 Nalidixic acid = 8 4 16 1 MIC X
14 Tetracycline = 1 0.25 1 1 MIC X
17 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
17 Erythromycin <= 1 0.5 2 1 MIC X
17 Gentamicin = 1 0.5 2 1 MIC X
17 Nalidixic acid = 8 4 16 1 MIC X
17 Tetracycline = 1 0.25 2 1 MIC X
18 Ciprofloxacin <= 0.12 0.03 0.125 1 MIC X
18 Erythromycin <= 1 0.25 2 1 MIC X
18 Gentamicin = 0.5 0.25 2 1 MIC X
18 Nalidixic acid = 4 4 16 1 MIC X
18 Tetracycline <= 0.5 0.25 1 1 MIC X
19 Ciprofloxacin <= 0.12 0.03 0.125 1 MIC X
19 Erythromycin <= 1 0.25 2 1 MIC X
19 Gentamicin = 0.5 0.25 2 1 MIC X
19 Nalidixic acid = 4 4 16 1 MIC X
19 Tetracycline <= 0.5 0.25 1 1 MIC X
20 Ciprofloxacin <= 0.12 0.06 0.25 1 MIC X
20 Erythromycin <= 1 0.5 2 1 MIC X
20 Gentamicin = 0.5 0.5 2 1 MIC X
20 Nalidixic acid = 8 4 16 1 MIC X
20 Tetracycline <= 0.5 0.25 2 1 MIC X
21 Ciprofloxacin = 0.12 0.03 0.125 1 MIC X
21 Erythromycin = 1 0.25 2 1 MIC X
21 Gentamicin = 0.25 0.25 2 1 MIC X
21 Nalidixic acid = 4 4 16 1 MIC X
21 Tetracycline = 0.5 0.25 1 1 MIC X
22 Ciprofloxacin <= 0.125 0.03 0.125 1 MIC X
22 Erythromycin <= 1 0.25 2 1 MIC X
22 Nalidixic acid = 2 4 16 0 MIC X
22 Tetracycline = 1 0.25 1 1 MIC X
23 Ciprofloxacin = 0.12 0.03 0.125 1 MIC X
23 Erythromycin <= 0.5 0.25 2 1 MIC X
23 Gentamicin = 1 0.25 2 1 MIC X
23 Nalidixic acid = 4 4 16 1 MIC X
23 Tetracycline = 0.5 0.25 1 1 MIC X
25 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
25 Erythromycin = 2 0.5 2 1 MIC X
25 Gentamicin = 0.25 0.5 2 0 MIC X
25 Nalidixic acid = 8 4 16 1 MIC X
25 Tetracycline = 2 0.25 2 1 MIC X
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26 Ciprofloxacin <= 0.12 0.06 0.25 1 MIC X
26 Erythromycin <= 1 0.5 2 1 MIC X
26 Gentamicin = 0.5 0.5 2 1 MIC X
26 Nalidixic acid = 8 4 16 1 MIC X
26 Tetracycline = 1 0.25 2 1 MIC X
29 Ciprofloxacin <= 0.12 0.06 0.25 1 MIC X
29 Erythromycin <= 1 0.5 2 1 MIC X
29 Gentamicin = 1 0.5 2 1 MIC X
29 Nalidixic acid = 8 4 16 1 MIC X
29 Tetracycline = 1 0.25 2 1 MIC X
30 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
30 Erythromycin <= 1 0.5 2 1 MIC X
30 Gentamicin = 1 0.5 2 1 MIC X
30 Nalidixic acid = 8 4 16 1 MIC X
30 Tetracycline = 1 0.25 2 1 MIC X
32 Ciprofloxacin <= 0.12 0.06 0.25 1 MIC X
32 Erythromycin <= 1 0.5 2 1 MIC X
32 Gentamicin = 1 0.5 2 1 MIC X
32 Nalidixic acid = 8 4 16 1 MIC X
32 Tetracycline = 1 0.25 2 1 MIC X
33 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
33 Erythromycin <= 1 0.5 2 1 MIC X
33 Gentamicin = 1 0.5 2 1 MIC X
33 Nalidixic acid = 16 4 16 1 MIC X
33 Tetracycline = 1 0.25 2 1 MIC X
34 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
34 Erythromycin = 2 0.5 2 1 MIC X
34 Gentamicin = 0.5 0.5 2 1 MIC X
34 Nalidixic acid = 8 4 16 1 MIC X
34 Tetracycline = 2 0.25 2 1 MIC X
36 Ciprofloxacin = 0.25 0.03 0.125 0 MIC X
36 Erythromycin <= 1 0.25 2 1 MIC X
36 Gentamicin = 1 0.25 2 1 MIC X
36 Nalidixic acid = 8 4 16 1 MIC X
36 Tetracycline = 2 0.25 1 0 MIC X
37 Ciprofloxacin <= 0.125 0.06 0.25 1 MIC X
37 Erythromycin <= 1 0.5 2 1 MIC X
37 Gentamicin = 1 0.5 2 1 MIC X
39 Ciprofloxacin <= 0.12 0.03 0.125 1 MIC X
39 Erythromycin <= 1 0.25 2 1 MIC X
39 Gentamicin = 0.5 0.25 2 1 MIC X
39 Nalidixic acid = 2 4 16 0 MIC X
39 Tetracycline = 1 0.25 1 1 MIC X
40 Ciprofloxacin <= 0.12 0.03 0.125 1 MIC X
40 Erythromycin <= 1 0.25 2 1 MIC X
40 Nalidixic acid = 4 4 16 1 MIC X
40 Tetracycline = 0.5 0.25 1 1 MIC X
56 Ciprofloxacin <= 0.12 0.03 0.125 1 MIC X
56 Erythromycin <= 1 0.25 2 1 MIC X
56 Gentamicin = 0.5 0.25 2 1 MIC X
56 Nalidixic acid = 4 4 16 1 MIC X
56 Tetracycline <= 0.5 0.25 1 1 MIC X
58 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
58 Erythromycin <= 1 0.5 2 1 MIC X
58 Gentamicin = 1 0.5 2 1 MIC X
58 Nalidixic acid = 8 4 16 1 MIC X
58 Tetracycline = 2 0.25 2 1 MIC X
59 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
59 Erythromycin <= 1 0.5 2 1 MIC X
59 Gentamicin = 1 0.5 2 1 MIC X
59 Nalidixic acid = 8 4 16 1 MIC X
59 Tetracycline = 1 0.25 2 1 MIC X
60 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
60 Erythromycin <= 1 0.5 2 1 MIC X
60 Gentamicin = 2 0.5 2 1 MIC X
60 Nalidixic acid = 8 4 16 1 MIC X
60 Tetracycline = 1 0.25 2 1 MIC X
MIC: Microbroth dilution
AGA: Agar dilution
Appendix 7a, page 1 of 3
Salmonella - expected and obtained interpretation
Antimicrobial Strain Panel Expected % R % S No. correct No. incorrect
Ampicillin AMP EURL S-12.1 Panel 1 R 100 0 31 0
EURL S-12.2 Panel 1 R 100 0 31 0
EURL S-12.3 Panel 1 R 100 0 31 0
EURL S-12.4 Panel 1 S 3 97 30 1
EURL S-12.5 Panel 1 S 0 100 31 0
EURL S-12.6 Panel 1 R 100 0 31 0
EURL S-12.7 Panel 1 R 100 0 31 0
EURL S-12.8 Panel 1 R 97 3 30 1
Azithromycin AZI EURL S-12.1 Panel 1 R 100 0 24 0
EURL S-12.2 Panel 1 S 4 96 22 1
EURL S-12.3 Panel 1 S 0 100 23 0
EURL S-12.4 Panel 1 S 0 100 23 0
EURL S-12.5 Panel 1 S 0 100 23 0
EURL S-12.6 Panel 1 S 0 100 23 0
EURL S-12.7 Panel 1 R 100 0 24 0
EURL S-12.8 Panel 1 R 100 0 23 0
Cefotaxime FOT EURL S-12.1 Panel 1 R 100 0 31 0
EURL S-12.2 Panel 1 R 100 0 31 0
EURL S-12.4* Panel 1* R* 40* 60* 18* 12*
EURL S-12.3 Panel 1 R 100 0 31 0
EURL S-12.5 Panel 1 S 0 100 31 0
EURL S-12.6 Panel 1 S 0 100 31 0
EURL S-12.7 Panel 1 R 100 0 31 0
EURL S-12.8 Panel 1 R 100 0 31 0
EURL S-12.1 Panel 2 R 100 0 31 0
EURL S-12.2 Panel 2 R 100 0 31 0
EURL S-12.3 Panel 2 R 100 0 31 0
EURL S-12.4* Panel 2* R* 56* 44* 14* 11*
EURL S-12.7 Panel 2 R 100 0 31 0
EURL S-12.8 Panel 2 R 100 0 31 0
Cefoxitin FOX EURL S-12.1 Panel 2 R 100 0 31 0
EURL S-12.2 Panel 2 S 3 97 30 1
EURL S-12.3 Panel 2 S 3 97 30 1
EURL S-12.4 Panel 2 R 100 0 26 0
EURL S-12.7 Panel 2 S 3 97 30 1
EURL S-12.8 Panel 2 R 100 0 31 0
Ceftazidime TAZ EURL S-12.1 Panel 1 R 100 0 31 0
EURL S-12.2 Panel 1 S 3 97 30 1
EURL S-12.3 Panel 1 R 100 0 31 0
EURL S-12.4 Panel 1 R 80 20 24 6
EURL S-12.5 Panel 1 S 0 100 31 0
EURL S-12.6 Panel 1 S 0 100 31 0
EURL S-12.7* Panel 1* S* 74* 26* 23* 8*
EURL S-12.8 Panel 1 R 100 0 31 0
EURL S-12.1 Panel 2 R 100 0 31 0
EURL S-12.2 Panel 2 S 0 100 31 0
EURL S-12.3 Panel 2 R 100 0 31 0
EURL S-12.4 Panel 2 R 88 12 22 3
EURL S-12.7* Panel 2* S* 74* 26* 23* 8*
EURL S-12.8 Panel 2 R 100 0 31 0
Chloramphenicol CHL EURL S-12.1 Panel 1 R 100 0 31 0
EURL S-12.2 Panel 1 S 0 100 31 0
EURL S-12.3 Panel 1 S 0 100 31 0
EURL S-12.4 Panel 1 S 0 100 31 0
EURL S-12.5 Panel 1 S 0 100 31 0
EURL S-12.6 Panel 1 S 0 100 31 0
EURL S-12.7 Panel 1 R 100 0 31 0
EURL S-12.8 Panel 1 R 97 3 30 1
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Ciprofloxacin CIP EURL S-12.1 Panel 1 R 97 3 30 1
EURL S-12.2 Panel 1 R 97 3 30 1
EURL S-12.3 Panel 1 R 100 0 31 0
EURL S-12.4 Panel 1 S 0 100 31 0
EURL S-12.5 Panel 1 S 0 100 31 0
EURL S-12.6 Panel 1 R 100 0 31 0
EURL S-12.7 Panel 1 S 0 100 31 0
EURL S-12.8 Panel 1 R 100 0 31 0
Colistin COL EURL S-12.1 Panel 1 S 0 100 31 0
EURL S-12.2 Panel 1 S 0 100 31 0
EURL S-12.3 Panel 1 S 0 100 31 0
EURL S-12.4 Panel 1 S 0 100 31 0
EURL S-12.5* Panel 1* R* 40* 60* 18* 12*
EURL S-12.6 Panel 1 S 0 100 31 0
EURL S-12.7 Panel 1 S 0 100 31 0
EURL S-12.8 Panel 1 S 0 100 31 0
Ertapenem ETP EURL S-12.1 Panel 2 R 100 0 31 0
EURL S-12.2 Panel 2 S 0 100 31 0
EURL S-12.3 Panel 2 S 0 100 31 0
EURL S-12.4 Panel 2 S 0 100 26 0
EURL S-12.7 Panel 2 S 0 100 31 0
EURL S-12.8 Panel 2 R 100 0 31 0
Gentamicin GEN EURL S-12.1 Panel 1 S 0 100 31 0
EURL S-12.2 Panel 1 S 0 100 31 0
EURL S-12.3 Panel 1 S 0 100 31 0
EURL S-12.4 Panel 1 S 0 100 31 0
EURL S-12.5 Panel 1 S 0 100 31 0
EURL S-12.6 Panel 1 R 100 0 31 0
EURL S-12.7 Panel 1 S 0 100 31 0
EURL S-12.8 Panel 1 R 100 0 31 0
Imipenem IMI EURL S-12.1 Panel 2 R 90 10 27 3
EURL S-12.2 Panel 2 S 0 100 31 0
EURL S-12.3 Panel 2 S 0 100 31 0
EURL S-12.4 Panel 2 S 0 100 26 0
EURL S-12.7 Panel 2 S 0 100 31 0
EURL S-12.8 Panel 2 R 97 3 30 1
Meropenem MER EURL S-12.1 Panel 1 R 100 0 31 0
EURL S-12.2 Panel 1 S 0 100 31 0
EURL S-12.3 Panel 1 S 0 100 30 0
EURL S-12.4 Panel 1 S 0 100 31 0
EURL S-12.5 Panel 1 S 0 100 31 0
EURL S-12.6 Panel 1 S 0 100 31 0
EURL S-12.7 Panel 1 S 0 100 31 0
EURL S-12.8 Panel 1 R 100 0 31 0
EURL S-12.1 Panel 2 R 100 0 31 0
EURL S-12.2 Panel 2 S 0 100 31 0
EURL S-12.3 Panel 2 S 0 100 31 0
EURL S-12.4 Panel 2 S 0 100 26 0
EURL S-12.7 Panel 2 S 0 100 31 0
EURL S-12.8 Panel 2 R 100 0 31 0
Nalidixic acid NAL EURL S-12.1 Panel 1 R 100 0 31 0
EURL S-12.2 Panel 1 R 100 0 31 0
EURL S-12.3 Panel 1 R 100 0 31 0
EURL S-12.4 Panel 1 S 0 100 31 0
EURL S-12.5 Panel 1 S 0 100 31 0
EURL S-12.6 Panel 1 R 100 0 31 0
EURL S-12.7 Panel 1 S 0 100 31 0
EURL S-12.8 Panel 1 R 100 0 31 0
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Sulfamethoxazole SMX EURL S-12.1 Panel 1 R 100 0 31 0
EURL S-12.2 Panel 1 S 0 100 31 0
EURL S-12.3 Panel 1 R 100 0 31 0
EURL S-12.4 Panel 1 S 10 90 28 3
EURL S-12.5 Panel 1 S 0 100 31 0
EURL S-12.6 Panel 1 R 100 0 31 0
EURL S-12.7 Panel 1 R 100 0 31 0
EURL S-12.8 Panel 1 R 90 10 28 3
Temocillin TRM EURL S-12.1 Panel 2 R 96 4 22 1
EURL S-12.2 Panel 2 S 4 96 22 1
EURL S-12.3 Panel 2 S 0 100 23 0
EURL S-12.4 Panel 2 R 100 0 17 0
EURL S-12.7 Panel 2 S 0 100 23 0
EURL S-12.8 Panel 2 R 96 4 22 1
Tetracycline TET EURL S-12.1 Panel 1 R 100 0 31 0
EURL S-12.2 Panel 1 R 100 0 31 0
EURL S-12.3 Panel 1 R 100 0 31 0
EURL S-12.4 Panel 1 S 0 100 31 0
EURL S-12.5 Panel 1 S 0 100 31 0
EURL S-12.6 Panel 1 R 100 0 31 0
EURL S-12.7 Panel 1 R 100 0 31 0
EURL S-12.8 Panel 1 S 0 100 31 0
Tigecycline TGC EURL S-12.1 Panel 1 S 0 100 31 0
EURL S-12.2 Panel 1 S 0 100 31 0
EURL S-12.3 Panel 1 S 0 100 31 0
EURL S-12.4 Panel 1 S 0 100 31 0
EURL S-12.5 Panel 1 S 0 100 31 0
EURL S-12.6 Panel 1 S 0 100 31 0
EURL S-12.7 Panel 1 S 3 97 30 1
EURL S-12.8 Panel 1 S 0 100 31 0
Trimethoprim TMP EURL S-12.1 Panel 1 R 100 0 31 0
EURL S-12.2 Panel 1 S 0 100 31 0
EURL S-12.3 Panel 1 R 100 0 31 0
EURL S-12.4 Panel 1 S 0 100 31 0
EURL S-12.5 Panel 1 S 0 100 31 0
EURL S-12.6 Panel 1 S 0 100 31 0
EURL S-12.7 Panel 1 R 100 0 31 0
EURL S-12.8 Panel 1 S 0 100 31 0
*Strain/antimicrobial-combination excluded from the evaluation
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Campylobacter  - expected and obtained interpretation
 
Antimicrobial Strain Expected % R % S No. correct No. incorrect
EURL C-12.1* S 0 100 23 0
EURL C-12.2 R 100 0 30 0
EURL C-12.3 S 0 100 30 0
EURL C-12.4 R 97 3 29 1
EURL C-12.5 R 97 3 29 1
EURL C-12.6 R 100 0 30 0
EURL C-12.7 S 3 97 29 1
EURL C-12.8 R 100 0 30 0
EURL C-12.1* S 0 100 23 0
EURL C-12.2 R 100 0 30 0
EURL C-12.3 S 0 100 30 0
EURL C-12.4 S 0 100 30 0
EURL C-12.5 S 0 100 30 0
EURL C-12.6 S 0 100 30 0
EURL C-12.7 S 0 100 30 0
EURL C-12.8 S 0 100 30 0
EURL C-12.1* S 0 100 23 0
EURL C-12.2 S 0 100 30 0
EURL C-12.3 S 0 100 30 0
EURL C-12.4 S 0 100 30 0
EURL C-12.5 S 0 100 30 0
EURL C-12.6 S 0 100 30 0
EURL C-12.7 S 0 100 30 0
EURL C-12.8 S 0 100 30 0
EURL C-12.1* S 0 100 23 0
EURL C-12.2 R 100 0 30 0
EURL C-12.3 S 0 100 30 0
EURL C-12.4 R 100 0 30 0
EURL C-12.5 R 97 3 29 1
EURL C-12.6 R 100 0 30 0
EURL C-12.7 S 3 97 29 1
EURL C-12.8 R 100 0 30 0
EURL C-12.1* S 0 100 23 0
EURL C-12.2 R 100 0 30 0
EURL C-12.3 R 100 0 30 0
EURL C-12.4 S 0 100 30 0
EURL C-12.5 R 97 3 29 1
EURL C-12.6 S 3 97 29 1
EURL C-12.7 S 0 100 30 0
EURL C-12.8 S 0 100 30 0
EURL C-12.1* S 0 100 23 0
EURL C-12.2 R 100 0 30 0
EURL C-12.3 R 93 7 28 2
EURL C-12.4 R 100 0 30 0
EURL C-12.5 R 100 0 30 0
EURL C-12.6 R 100 0 30 0
EURL C-12.7 S 3 97 29 1
EURL C-12.8 R 100 0 30 0
*Results excluded for six users that appear to have been testing a contamination 
Ciprofloxacin, CIP
Tetracycline, TET
Streptomycin, STR
Nalidixic acid, NAL
Gentamicin, GEN
Erythromycin, ERY
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Deviations - Salmonella
Lab no. Strain Panel Antimicrobial Obtained MIC value
Expected 
MIC-value
Obtained 
interpretation
Expected 
interpretation
2 EURL S-12.4 ESBL-categorization None Presumptive AmpC
4 EURL S-12.7 1 Tigecycline TGC 2 1 R S
9 EURL S-12.1 2 Imipenem IMI 1 2 S R
12 EURL S-12.4 1 Sulfamethoxazole SMX 1024 64 R S
18 EURL S-12.4 1 Sulfamethoxazole SMX > 1024 64 R S
19 EURL S-12.2 2 Cefoxitin FOX 2 4 R S
19 EURL S-12.3 2 Cefoxitin FOX 4 4 R S
19 EURL S-12.7 2 Cefoxitin FOX 4 8 R S
21 EURL S-12.4 1 Ceftazidime TAZ 1 4 S R
21 EURL S-12.4 ESBL-categorization None Presumptive AmpC
22 EURL S-12.2 1 Ceftazidime TAZ 1 1 R S
23 EURL S-12.8 1 Sulfamethoxazole SMX 256 > 1024 S R
26 EURL S-12.1 2 Imipenem IMI = 0.5 2 S R
26 EURL S-12.1 2 Temocillin TRM 32 64 S R
26 EURL S-12.4 1 Sulfamethoxazole SMX 512 64 R S
26 EURL S-12.8 1 Chloramphenicol CHL 16 64 S R
26 EURL S-12.8 2 Imipenem IMI 1 8 S R
26 EURL S-12.8 2 Temocillin TRM 32 > 128 S R
30 EURL S-12.4 1 Ceftazidime TAZ <= 0.5 4 S R
30 EURL S-12.4 ESBL-categorization None Presumptive AmpC
33 EURL S-12.4 2 Ceftazidime TAZ 2 4 S R
34 EURL S-12.4 1 Ceftazidime TAZ 2 4 S R
34 EURL S-12.4 2 Ceftazidime TAZ 2 4 S R
34 EURL S-12.4 ESBL-categorization None Presumptive AmpC
36 EURL S-12.4 2 Ceftazidime TAZ 4 4 S R
36 EURL S-12.8 1 Sulfamethoxazole SMX <= 8 > 1024 S R
37 EURL S-12.8 1 Ampicillin AMP > 64 > 64 S R
39 EURL S-12.1 2 Imipenem IMI 1 2 S R
40 EURL S-12.4 1 Ampicillin AMP 64 2 R S
42 EURL S-12.1 1 Ciprofloxacin CIP 8 > 8 S R
42 EURL S-12.2 1 Ciprofloxacin CIP = 0.25 = 0.5 S R
42 EURL S-12.2 2 Temocillin TRM 4 4 R S
42 EURL S-12.4 1 Ceftazidime TAZ 2 4 S R
42 EURL S-12.4 ESBL-categorization None Presumptive AmpC
42 EURL S-12.8 1 Sulfamethoxazole SMX <= 8 > 1024 S R
45 EURL S-12.2 1 Azithromycin AZI 4 8 R S
45 EURL S-12.4 1 Ceftazidime TAZ 2 4 S R
45 EURL S-12.4 ESBL-categorization None Presumptive AmpC
58 EURL S-12.4 1 Ceftazidime TAZ <= 0.5 4 S R
58 EURL S-12.4 ESBL-categorization None Presumptive AmpC
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Deviations - Campylobacter
Lab no. Strain Antimicrobial Obtained MIC value
Expected 
MIC-value
Obtained 
interpretation
Expected 
interpretation
11 EURL C-12.3 Tetracycline TET <=       0.5 8 S R
42 EURL C-12.3 Tetracycline TET 16 8 S R
29 EURL C-12.4 Ciprofloxacin CIP 8 8 S R
39 EURL C-12.5 Ciprofloxacin CIP 4 4 S R
39 EURL C-12.5 Nalidixic acid NAL 16 64 S R
40 EURL C-12.5 Streptomycin STR <=       0.25 >      16 S R
40 EURL C-12.6 Streptomycin STR 16 2 R S
40 EURL C-12.7 Ciprofloxacin CIP 16 <=       0.12 R S
40 EURL C-12.7 Nalidixic acid NAL 64 4 R S
40 EURL C-12.7 Tetracycline TET >      64 <=       0.5 R S
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Genotypic characterization (optional); genes detected in the ESBL-, AmpC, and carbapenemase producing Salmonella  strains
1 EURL S-12.1 CMY -16 Whole genome sequenced
1 EURL S-12.2 CTX M-9 Whole genome sequenced
1 EURL S-12.2 TEM -1B Whole genome sequenced
1 EURL S-12.3 CTX M-14 Whole genome sequenced
1 EURL S-12.7 CTX M-14 Whole genome sequenced
1 EURL S-12.8 CTX M-15 Whole genome sequenced
1 EURL S-12.8 NDM -1 Whole genome sequenced
1 EURL S-12.8 OXA -10 Whole genome sequenced
1 EURL S-12.8 OXA -9 Whole genome sequenced
1 EURL S-12.8 OXA -1 Whole genome sequenced
1 EURL S-12.8 TEM -1B Whole genome sequenced
2 EURL S-12.1 CMY
2 EURL S-12.1 NDM
2 EURL S-12.2 CTX
2 EURL S-12.2 TEM
2 EURL S-12.3 CTX
2 EURL S-12.7 CTX
2 EURL S-12.8 DHA
2 EURL S-12.8 NDM
4 EURL S-12.1 CMY -16 PCR (published)
4 EURL S-12.1 NDM -1 PCR (published)
4 EURL S-12.2 CTX M-9 PCR (published)
4 EURL S-12.2 TEM PCR (published)
4 EURL S-12.3 CTX M-14 PCR (published)
4 EURL S-12.7 CTX M-14 PCR (published)
4 EURL S-12.8 NDM -1 PCR (published)
17 EURL S-12.1 CMY -16 Whole genome sequenced ResFinder 3.0
17 EURL S-12.1 CMY PCR (published) Zhao et al. (2001)
17 EURL S-12.1 NDM -1 Whole genome sequenced ResFinder 3.0
17 EURL S-12.1 NDM -1 PCR (published) Poirel et al. (2011)
17 EURL S-12.2 CTX M-9 PCR (published) Batchelor et al. (2005)
17 EURL S-12.2 CTX M-9 Whole genome sequenced ResFinder 3.0
17 EURL S-12.2 TEM -1B Whole genome sequenced ResFinder 3.0
17 EURL S-12.2 TEM PCR (published) Guerra et al. (2001)
17 EURL S-12.3 CTX M-14 PCR (published) Roschanski et al. [2014]
17 EURL S-12.3 CTX M-14 Whole genome sequenced ResFinder 3.0
17 EURL S-12.7 CTX M-14 Whole genome sequenced ResFinder 3.0
17 EURL S-12.7 CTX M-14 PCR (published) Roschanski et al. [2014]
17 EURL S-12.8 CTX M-15 Whole genome sequenced Resfinder 3.0
17 EURL S-12.8 CTX M-15 PCR (published) Batchelor et al (2005)
17 EURL S-12.8 DHA -1 Whole genome sequenced Resfinder 3.0
17 EURL S-12.8 NDM -1 PCR (published) Poirel et al. (2011)
17 EURL S-12.8 NDM -1 Whole genome sequenced Resfinder 3.0
17 EURL S-12.8 OXA -10 Whole genome sequenced Resfinder 3.0
Method Reference Primer 5 3 Primer 3 5Labno Strain Genetype Gene number
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17 EURL S-12.8 OXA -10 PCR (published) Guerra et al. (2000)
17 EURL S-12.8 OXA -9 Whole genome sequenced Resfinder 3.0
17 EURL S-12.8 OXA -1 Whole genome sequenced Resfinder 3.0
17 EURL S-12.8 TEM -1 Whole genome sequenced Resfinder 3.0
17 EURL S-12.8 TEM PCR (published) Olesen et al. (2004)
20 EURL S-12.1 CMY -16 Whole genome sequenced Resfinder
20 EURL S-12.1 NDM -1 Whole genome sequenced Resfinder
20 EURL S-12.2 CTX M-9 Whole genome sequenced resfinder
20 EURL S-12.2 TEM -1B Whole genome sequenced resfinder
20 EURL S-12.3 CTX M-14 Whole genome sequenced Resfinder
20 EURL S-12.7 CTX M-14 Whole genome sequenced resfinder
20 EURL S-12.8 CTX M-15 Whole genome sequenced resfinder
20 EURL S-12.8 NDM -1 Whole genome sequenced resfinder
20 EURL S-12.8 OXA -10 Whole genome sequenced resfinder
20 EURL S-12.8 OXA -9 Whole genome sequenced resfinder
20 EURL S-12.8 OXA -1 Whole genome sequenced resfinder
21 EURL S-12.1 CMY PCR (published) Wiesner M 2009 taaccacccagtcacgc cagtagcgagactgcgca
21 EURL S-12.1 NDM PCR (published) Poirel L 2011 ggtttggcgatctggttttc cggaatggctcatcacgatc
21 EURL S-12.2 CTX PCR (published) Carattoli A 2008 cccatggttaaaaaatcactgc cagcgcttttgccgtctaag
21 EURL S-12.3 CTX PCR (published) Carattoli A 2008 cccatggttaaaaaatcactgc cagcgcttttgccgtctaag
21 EURL S-12.7 CTX PCR (published) Carattoli A 2008 cccatggttaaaaaatcactgc cagcgcttttgccgtctaag
21 EURL S-12.8 CTX PCR (published) Carattoli A 2008 cccatggttaaaaaatcactgc cagcgcttttgccgtctaag
21 EURL S-12.8 NDM PCR (published) Poirel L 2011 ggtttggcgatctggttttc cggaatggctcatcacgatc
22 EURL S-12.1 CMY PCR (published) Kim et al., 2009 AGC GAT CCG GTC ACG AAA TA CCC GTT TTA TGC ACC CAT GA
22 EURL S-12.1 NDM PCR (published) Poirel et al., 2011 GGT TTG GCG ATC TGG TTT TC CGG AAT GGC TCA TCA CGA TC
22 EURL S-12.2 CTX PCR (published) Kim et al., 2009 GAC AAA GAG AGT GCA ACG GAT G TCA GTG CGA TCC AGA CGA AA
22 EURL S-12.2 TEM PCR (published) Kim et al., 2009 AGT GCT GCC ATA ACC ATG AGT G CTG ACT CCC CGT CGT GTA GAT A
22 EURL S-12.3 CTX PCR (published) Kim et al., 2009 GAC AAA GAG AGT GCA ACG GAT G TCA GTG CGA TCC AGA CGA AA
22 EURL S-12.7 CTX PCR (published) Kim et al., 2009 GAC AAA GAG AGT GCA ACG GAT G TCA GTG CGA TCC AGA CGA AA
22 EURL S-12.8 CTX PCR (published) Kim et al., 2009 TCC AGA ATA AGG AAT CCC ATG G TGC TTT ACC CAG CGT CAG AT
22 EURL S-12.8 DHA PCR (published) Kim et al., 2009 GTG GTG GAC AGC ACC ATT AAA CCT GCG GTA TAG GTA GCC AGA T
22 EURL S-12.8 NDM PCR (published) Poirel et al., 2011 GGT TTG GCG ATC TGG TTT TC CGG AAT GGC TCA TCA CGA TC
22 EURL S-12.8 OXA PCR (published) Kim et al., 2009 ATT ATC TAC AGC AGC GCC AGT G TGC ATC CAC GTC TTT GGT G
22 EURL S-12.8 TEM PCR (published) Kim et al., 2009 AGT GCT GCC ATA ACC ATG AGT G CTG ACT CCC CGT CGT GTA GAT A
25 EURL S-12.1 CMY -16 PCR (in-house)
25 EURL S-12.1 NDM -1 PCR (published)
25 EURL S-12.2 CTX M-9 PCR (published)
25 EURL S-12.2 TEM -1B PCR (published)
25 EURL S-12.3 CTX M-14 PCR (published)
25 EURL S-12.7 CTX M-14 PCR (published)
25 EURL S-12.8 CTX M-15 PCR (published)
25 EURL S-12.8 DHA -1 PCR (published)
25 EURL S-12.8 NDM -1 PCR (published)
25 EURL S-12.8 TEM -1B PCR (published)
32 EURL S-12.1 CMY -16 PCR (published) A.AGE.CHEM2006.ClinMicr1999-37
32 EURL S-12.1 NDM -1 PCR (published) L. Poirel et al 2011
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32 EURL S-12.2 CTX M-9 PCR (published) PediatrInfectDisJ28:814-818
32 EURL S-12.2 TEM -1 PCR (published) AntimicrAgentsChemotherap2009
32 EURL S-12.3 CMY -16 PCR (published) A.AGE.CHEM2006.ClinMicr1999-37
32 EURL S-12.3 CTX M-14 PCR (published) PediatrInfectDisJ28:814-818
32 EURL S-12.7 CTX M-14 PCR (published) PediatrInfectDisJ28:814-818
32 EURL S-12.8 CTX M-15 PCR (published) PediatrInfectDisJ28:814-818
32 EURL S-12.8 NDM -1 PCR (published) L. Poirel et al 2011
32 EURL S-12.8 OXA -17 PCR (published) Voets  et al.  2011
32 EURL S-12.8 OXA -1 PCR (published) J. Antimic.Chemothe(2009) 64
32 EURL S-12.8 TEM -1 PCR (published) AntimicrAgentsChemotherap2009
33 EURL S-12.1 CMY
PCR (published)
Perez-Perez, F. J. and N. D. Hanson (2002). Detection 
of plasmid-mediated AmpC beta-lactamase genes in 
clinical isolates by using multiplex PCR, J Clin Microbiol 
40(6): 2153-62.
TGGCCAGAACTGACAGGCAAA TTTCTCCTGAACGTGGCTGGC
33 EURL S-12.1 NDM
PCR (published)
Poirel et al.(2011)”Multiplex PCR for detection of 
acquired carbapenemase genes”, Diagnostic 
Microbiology & Infectious Disease, 70(1), 119-123, 2011
GGTTTGGCGATCTGGTTTTC CGGAATGGCTCATCACGATC
33 EURL S-12.2 CTX M-9
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
CAAAGAGARTGCAACGGATG ATTGGAAAGCGTTCATCACC
33 EURL S-12.2 TEM PCR (published) Fang, H., F. Ataker, et al. (2008).  J Clin Microbiol 46(2): 707-12. CGCCGCATACACTATTCTCAGAATGA ACGCTCACCGGCTCCAGATTTAT
33 EURL S-12.3 CTX M-9
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
CAAAGAGARTGCAACGGATG ATTGGAAAGCGTTCATCACC
33 EURL S-12.7 CTX M-9
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
CAAAGAGARTGCAACGGATG ATTGGAAAGCGTTCATCACC
33 EURL S-12.8 CTX M-1
PCR (published)
Woodford, N., E. J. Fagan, et al. (2006). Multiplex PCR 
for rapid detection of genes encoding CTX-M extended-
spectrum ß-lactamases. J Antimicrob Chemother 57(1): 
154-5.
AAAAATCACTGCGYCAGTTC AGCTTATTCATCGCCACGTT
33 EURL S-12.8 DHA
PCR (published)
Perez-Perez, F. J. and N. D. Hanson (2002). Detection 
of plasmid-mediated AmpC beta-lactamase genes in 
clinical isolates by using multiplex PCR, J Clin Microbiol 
40(6): 2153-62.
AACTTTCACAGGTGTGCTGGGT CCGTACGCATACTGGCTTTGC
33 EURL S-12.8 NDM
PCR (published)
Poirel et al.(2011)”Multiplex PCR for detection of 
acquired carbapenemase genes”, Diagnostic 
Microbiology & Infectious Disease, 70(1), 119-123, 2011
GGTTTGGCGATCTGGTTTTC CGGAATGGCTCATCACGATC
33 EURL S-12.8 OXA -1 PCR (published) Fang, H., F. Ataker, et al. (2008).  J Clin Microbiol 46(2): 707-12. ACACAATACATATCAACTTCGC AGTGTGTTTAGAATGGTGATC
33 EURL S-12.8 TEM PCR (published) Fang, H., F. Ataker, et al. (2008).  J Clin Microbiol 46(2): 707-12. CGCCGCATACACTATTCTCAGAATGA ACGCTCACCGGCTCCAGATTTAT
36 EURL S-12.1 NDM -1 PCR (published) S.Mushtaq et. al. J. Antimicrob. Chemother. (2011) 66 (9): 2002-2005. doi: 10.1093/jac/dkr226 GGGCAGTCGCTTCCAACGGT GTAGTGCTCAGTGTCGGCAT
36 EURL S-12.2 CTX M-9 PCR (published) Hasman et al. J Antimicrob Chemother. 2005 Jul;56(1):115-21. ATGTGCAGYACCAGTAARGTKATGGC TGGGTRAARTARGTSACCAGAAYCAGCGG
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36 EURL S-12.2 TEM -1B PCR (published) Briñas et al. Antimicrob Agents Chemother. 2002 Oct;46(10):3156-63. TTCTTGAAGACGAAAGGGC ACGCTCAGTGGAACGAAAAC
36 EURL S-12.3 CTX M-14 PCR (published) Hasman et al. J Antimicrob Chemother. 2005 Jul;56(1):115-21. ATGTGCAGYACCAGTAARGTKATGGC TGGGTRAARTARGTSACCAGAAYCAGCGG
36 EURL S-12.7 CTX M-14 PCR (published) Hasman et al. J Antimicrob Chemother. 2005 Jul;56(1):115-21. ATGTGCAGYACCAGTAARGTKATGGC TGGGTRAARTARGTSACCAGAAYCAGCGG
36 EURL S-12.8 NDM -1 PCR (published) S.Mushtaq et. al. J. Antimicrob. Chemother. (2011) 66 (9): 2002-2005. doi: 10.1093/jac/dkr226 GGGCAGTCGCTTCCAACGGT GTAGTGCTCAGTGTCGGCAT
58 EURL S-12.1 CMY PCR (published) EURL protocol 5'-ATGATGAAAAAATCGTTATGCTGC-3' 5'-GCTTTTCAAGAATGCGCCAGG-3'
58 EURL S-12.1 NDM PCR (published) EURL protocol 5'-GGTTTGGCGATCTGGTTTTC-3' 5'-CGGAATGGCTCATCACGATC-3'
58 EURL S-12.2 CTX
PCR (published) EURL protocol 5’-ATGTGCAGYACCAGTAARGTKATGGC-3’
5’-
TGGGTRAARTARGTSACCAGAAYSAGCGG-
3’
58 EURL S-12.2 TEM PCR (published) EURL protocol 5'-GCGGAACCCCTATTTG-3' 5'-ACCAATGCTTAATCAGTGAG-3'
58 EURL S-12.3 CTX
PCR (published) EURL protocol 5’-ATGTGCAGYACCAGTAARGTKATGGC-3’
5’-
TGGGTRAARTARGTSACCAGAAYSAGCGG-
3’
58 EURL S-12.7 CTX
PCR (published) EURL protocol 5’-ATGTGCAGYACCAGTAARGTKATGGC-3’
5’-
TGGGTRAARTARGTSACCAGAAYSAGCGG-
3’
58 EURL S-12.8 CTX
PCR (published) EURL protocol 5’-ATGTGCAGYACCAGTAARGTKATGGC-3’
5’-
TGGGTRAARTARGTSACCAGAAYSAGCGG-
3’
58 EURL S-12.8 NDM PCR (published) EURL protocol 5'-GGTTTGGCGATCTGGTTTTC-3' 5'-CGGAATGGCTCATCACGATC-3'
58 EURL S-12.8 TEM PCR (published) EURL protocol 5'-GCGGAACCCCTATTTG-3' 5'-ACC AAT GCT TAA TCA GTG AG-3'
Legend: 
Fields shaded grey indicate that the gene was expected
Genes in bold and white font, were detected but not expected 
Note: TEM-1 does not confer ESBL-production and is as such not included as an expected result. TEM-1 or TEM-1B was, however, present in S-12.2 and S-12.8
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1 EURL S-12.2 blaTEM-1b coding for TEM-1
1 EURL S-12.3 blaCTX-M-14b coding for CTX-M-14
1 EURL S-12.6 blaTEM-1b coding for TEM-1
1 EURL S-12.8 blaTEM-1b coding for TEM-1;
partial blaDHA gene detected
17 EURL S-12.3 blaCTX-M-14b (100.00%, 876/876)
17 EURL S-12.8 DHA partially detected: blaDHA-1 (100.00%, 1140/796), blaTEM-1A (99.88%, 861/861)
25 EURL S-12.4 Despite resistance against cefotaxime and ceftazidime no resistance genes could be detected with 
microarray (CT103).
32 EURL S-12.1 SPM Gene tested for/not detected  (L. Poirel et al 2011)
IMP Gene: Gene Number should be blank , the gene has not been detected (we can´t change it in the 
database)
32 EURL S-12.2 SPM Gene tested for/not detected  (L. Poirel et al 2011)
32 EURL S-12.3 SPM Gene tested for/not detected  (L. Poirel et al 2011)
32 EURL S-12.4 SPM Gene tested for/not detected  (L. Poirel et al 2011)
32 EURL S-12.7 SPM Gene tested for/not detected  (L. Poirel et al 2011)
32 EURL S-12.8 SPM Gene tested for/not detected  (L. Poirel et al 2011)
33 EURL S-12.1 If suspected for ESBL isolates are tested for CTX-M-1, -2 -9 -8 -25, SHV, TEM, OXA-1 groups
If suspected for ampC isolates are tested for the above mentioned gene-groups and the following 
genegroups MOX, CIT, DHA, ACC, ACT and FOX
For supected carbapenemase we test for the following genes: NDM, KPC, OXA-48, VIM, IMP
33 EURL S-12.2 If suspected for ESBL isolates are tested for CTX-M-1, -2 -9 -8 -25, SHV, TEM, OXA-1 groups
If suspected for ampC isolates are tested for the above mentioned gene-groups and the following 
genegroups MOX, CIT, DHA, ACC, ACT and FOX
For supected carbapenemase we test for the following genes: NDM, KPC, OXA-48, VIM, IMP
33 EURL S-12.3 If suspected for ESBL isolates are tested for CTX-M-1, -2 -9 -8 -25, SHV, TEM, OXA-1 groups
If suspected for ampC isolates are tested for the above mentioned gene-groups and the following 
genegroups MOX, CIT, DHA, ACC, ACT and FOX
For supected carbapenemase we test for the following genes: NDM, KPC, OXA-48, VIM, IMP
33 EURL S-12.4 If suspected for ESBL isolates are tested for CTX-M-1, -2 -9 -8 -25, SHV, TEM, OXA-1 groups
If suspected for ampC isolates are tested for the above mentioned gene-groups and the following 
genegroups MOX, CIT, DHA, ACC, ACT and FOX
For supected carbapenemase we test for the following genes: NDM, KPC, OXA-48, VIM, IMP
33 EURL S-12.7 If suspected for ESBL isolates are tested for CTX-M-1, -2 -9 -8 -25, SHV, TEM, OXA-1 groups
If suspected for ampC isolates are tested for the above mentioned gene-groups and the following 
genegroups MOX, CIT, DHA, ACC, ACT and FOX
For supected carbapenemase we test for the following genes: NDM, KPC, OXA-48, VIM, IMP
33 EURL S-12.8 If suspected for ESBL isolates are tested for CTX-M-1, -2 -9 -8 -25, SHV, TEM, OXA-1 groups
If suspected for ampC isolates are tested for the above mentioned gene-groups and the following 
genegroups MOX, CIT, DHA, ACC, ACT and FOX
For supected carbapenemase we test for the following genes: NDM, KPC, OXA-48, VIM, IMP
58 EURL S-12.1 We performed for mcr1 and mcr2 genes and the genes were not detected.
We also performed for CTX-M1 gene and CTX-M9 gene and the genes were not detected.
For OXA gene, we performed for OXA-48.
58 EURL S-12.2 We also performed for CTX-M9 gene with EURL primers and the gene was detected.
We performed for CTX-M1 gene with EURL primers and the gene was not detected.
We performed for mcr1 and mcr2 genes with EURL primers and the genes were not detected.
For OXA gene, we performed for OXA-48.
58 EURL S-12.3 We also performed for CTX-M9 gene with EURL primers and the gene was detected.
We performed for CTX-M1 gene with EURL primers and the gene was not detected.
We performed for mcr1 and mcr2 genes with EURL primers and the genes were not detected.
For OXA gene, we performed for OXA-48 with EURL primers.
58 EURL S-12.4 We also performed for CTX-M1 gene and CTX-M9 gene with EURL primers and the genes were not 
detected.
We performed for mcr1 and mcr2 genes with EURL primers and the genes were not detected.
For gene OXA we performed for OXA-48 gene with EURL primers and the gene was not detected.
58 EURL S-12.5 We performed for mcr1 and mcr2 genes with EURL primers and the genes were not detected.
We also performed for CTX-M1 gene and CTX-M9 gene with EURL primers.
For OXA gene, we performed for OXA-48 with EURL primers.
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58 EURL S-12.6 We performed for mcr1 and mcr2 genes with EURL primers and the genes were not detected.
We also performed for CTX-M1 gene and CTX-M9 gene with EURL primers and the genes were not 
detected.
For gene OXA, we performed for OXA-48 gene with EURL primers.
58 EURL S-12.7 For gene CTX-M, we performed with EURL primers and the gene was detected.
We also performed for CTX-M9 gene with EURL primers and the gene was detected.
We also performed for CTX-M1 gene and the gene was nor detected.
We performed for mcr1 and mcr2 genes with EURL primers and the genes were not detected.
For gene OXA, we performed for OXA-48 with EURL primers.
58 EURL S-12.8 We performed for CTX-M1 gene with EURL primers and it was detected.
We performed for CTX-M9 gene with EURL primers and it was not detected.
We performed for mcr1 and mcr2 genes with EURL primers and the genes were not detected.
For OXA gene we performed for OXA-48 gene with EURL primers.
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